3csy › Citations

Structure of the Ebola virus glycoprotein bound to an antibody from a human survivor.

Lee JE, Fusco ML, Hessell AJ, Oswald WB, Burton DR, Saphire EO
Nature 454 177-82 (2008)
Cited: 468 times
EuropePMC logo PMID: 18615077

Abstract

Ebola virus (EBOV) entry requires the surface glycoprotein (GP) to initiate attachment and fusion of viral and host membranes. Here we report the crystal structure of EBOV GP in its trimeric, pre-fusion conformation (GP1+GP2) bound to a neutralizing antibody, KZ52, derived from a human survivor of the 1995 Kikwit outbreak. Three GP1 viral attachment subunits assemble to form a chalice, cradled by the GP2 fusion subunits, while a novel glycan cap and projected mucin-like domain restrict access to the conserved receptor-binding site sequestered in the chalice bowl. The glycocalyx surrounding GP is likely central to immune evasion and may explain why survivors have insignificant neutralizing antibody titres. KZ52 recognizes a protein epitope at the chalice base where it clamps several regions of the pre-fusion GP2 to the amino terminus of GP1. This structure provides a template for unravelling the mechanism of EBOV GP-mediated fusion and for future immunotherapeutic development.

Reviews - 3csy mentioned but not cited (11)

  1. Filovirus entry: a novelty in the viral fusion world. Hunt CL, Lennemann NJ, Maury W. Viruses 4 258-275 (2012)
  2. A new player in the puzzle of filovirus entry. White JM, Schornberg KL. Nat Rev Microbiol 10 317-322 (2012)
  3. Structural basis for differential neutralization of ebolaviruses. Bale S, Dias JM, Fusco ML, Hashiguchi T, Wong AC, Liu T, Keuhne AI, Li S, Woods VL, Chandran K, Dye JM, Saphire EO. Viruses 4 447-470 (2012)
  4. Filovirus entry into cells - new insights. Miller EH, Chandran K. Curr Opin Virol 2 206-214 (2012)
  5. The secret life of viral entry glycoproteins: moonlighting in immune evasion. Cook JD, Lee JE. PLoS Pathog 9 e1003258 (2013)
  6. Role of electrostatic repulsion in controlling pH-dependent conformational changes of viral fusion proteins. Harrison JS, Higgins CD, O'Meara MJ, Koellhoffer JF, Kuhlman BA, Lai JR. Structure 21 1085-1096 (2013)
  7. Cells under siege: viral glycoprotein interactions at the cell surface. Bowden TA, Jones EY, Stuart DI. J Struct Biol 175 120-126 (2011)
  8. Filovirus proteins for antiviral drug discovery: A structure/function analysis of surface glycoproteins and virus entry. Martin B, Hoenen T, Canard B, Decroly E. Antiviral Res 135 1-14 (2016)
  9. Max Bergmann lecture protein epitope mimetics in the age of structural vaccinology. Robinson JA. J Pept Sci 19 127-140 (2013)
  10. 50 Years of structural immunology. Wilson IA, Stanfield RL. J Biol Chem 296 100745 (2021)
  11. Structural Biology Illuminates Molecular Determinants of Broad Ebolavirus Neutralization by Human Antibodies for Pan-Ebolavirus Therapeutic Development. Murin CD, Gilchuk P, Crowe JE, Ward AB. Front Immunol 12 808047 (2021)

Articles - 3csy mentioned but not cited (81)

  1. Structure and immune recognition of trimeric pre-fusion HIV-1 Env. Pancera M, Zhou T, Druz A, Georgiev IS, Soto C, Gorman J, Huang J, Acharya P, Chuang GY, Ofek G, Stewart-Jones GB, Stuckey J, Bailer RT, Joyce MG, Louder MK, Tumba N, Yang Y, Zhang B, Cohen MS, Haynes BF, Mascola JR, Morris L, Munro JB, Blanchard SC, Mothes W, Connors M, Kwong PD. Nature 514 455-461 (2014)
  2. Structure of the Ebola virus glycoprotein bound to an antibody from a human survivor. Lee JE, Fusco ML, Hessell AJ, Oswald WB, Burton DR, Saphire EO. Nature 454 177-182 (2008)
  3. Ebola virus entry requires the host-programmed recognition of an intracellular receptor. Miller EH, Obernosterer G, Raaben M, Herbert AS, Deffieu MS, Krishnan A, Ndungo E, Sandesara RG, Carette JE, Kuehne AI, Ruthel G, Pfeffer SR, Dye JM, Whelan SP, Brummelkamp TR, Chandran K. EMBO J 31 1947-1960 (2012)
  4. Ebola Viral Glycoprotein Bound to Its Endosomal Receptor Niemann-Pick C1. Wang H, Shi Y, Song J, Qi J, Lu G, Yan J, Gao GF. Cell 164 258-268 (2016)
  5. Structures of protective antibodies reveal sites of vulnerability on Ebola virus. Murin CD, Fusco ML, Bornholdt ZA, Qiu X, Olinger GG, Zeitlin L, Kobinger GP, Ward AB, Saphire EO. Proc Natl Acad Sci U S A 111 17182-17187 (2014)
  6. Isolation of potent neutralizing antibodies from a survivor of the 2014 Ebola virus outbreak. Bornholdt ZA, Turner HL, Murin CD, Li W, Sok D, Souders CA, Piper AE, Goff A, Shamblin JD, Wollen SE, Sprague TR, Fusco ML, Pommert KB, Cavacini LA, Smith HL, Klempner M, Reimann KA, Krauland E, Gerngross TU, Wittrup KD, Saphire EO, Burton DR, Glass PJ, Ward AB, Walker LM. Science 351 1078-1083 (2016)
  7. Structural analysis of B-cell epitopes in antibody:protein complexes. Kringelum JV, Nielsen M, Padkjær SB, Lund O. Mol Immunol 53 24-34 (2013)
  8. Toremifene interacts with and destabilizes the Ebola virus glycoprotein. Zhao Y, Ren J, Harlos K, Jones DM, Zeltina A, Bowden TA, Padilla-Parra S, Fry EE, Stuart DI. Nature 535 169-172 (2016)
  9. A forward genetic strategy reveals destabilizing mutations in the Ebolavirus glycoprotein that alter its protease dependence during cell entry. Wong AC, Sandesara RG, Mulherkar N, Whelan SP, Chandran K. J Virol 84 163-175 (2010)
  10. Cross-Reactive and Potent Neutralizing Antibody Responses in Human Survivors of Natural Ebolavirus Infection. Flyak AI, Shen X, Murin CD, Turner HL, David JA, Fusco ML, Lampley R, Kose N, Ilinykh PA, Kuzmina N, Branchizio A, King H, Brown L, Bryan C, Davidson E, Doranz BJ, Slaughter JC, Sapparapu G, Klages C, Ksiazek TG, Saphire EO, Ward AB, Bukreyev A, Crowe JE. Cell 164 392-405 (2016)
  11. Protective efficacy of neutralizing monoclonal antibodies in a nonhuman primate model of Ebola hemorrhagic fever. Marzi A, Yoshida R, Miyamoto H, Ishijima M, Suzuki Y, Higuchi M, Matsuyama Y, Igarashi M, Nakayama E, Kuroda M, Saijo M, Feldmann F, Brining D, Feldmann H, Takada A. PLoS One 7 e36192 (2012)
  12. Antibodies from a Human Survivor Define Sites of Vulnerability for Broad Protection against Ebolaviruses. Wec AZ, Herbert AS, Murin CD, Nyakatura EK, Abelson DM, Fels JM, He S, James RM, de La Vega MA, Zhu W, Bakken RR, Goodwin E, Turner HL, Jangra RK, Zeitlin L, Qiu X, Lai JR, Walker LM, Ward AB, Dye JM, Chandran K, Bornholdt ZA. Cell 169 878-890.e15 (2017)
  13. Systematic Analysis of Monoclonal Antibodies against Ebola Virus GP Defines Features that Contribute to Protection. Saphire EO, Schendel SL, Fusco ML, Gangavarapu K, Gunn BM, Wec AZ, Halfmann PJ, Brannan JM, Herbert AS, Qiu X, Wagh K, He S, Giorgi EE, Theiler J, Pommert KBJ, Krause TB, Turner HL, Murin CD, Pallesen J, Davidson E, Ahmed R, Aman MJ, Bukreyev A, Burton DR, Crowe JE, Davis CW, Georgiou G, Krammer F, Kyratsous CA, Lai JR, Nykiforuk C, Pauly MH, Rijal P, Takada A, Townsend AR, Volchkov V, Walker LM, Wang CI, Zeitlin L, Doranz BJ, Ward AB, Korber B, Kobinger GP, Andersen KG, Kawaoka Y, Alter G, Chandran K, Dye JM, Viral Hemorrhagic Fever Immunotherapeutic Consortium. Cell 174 938-952.e13 (2018)
  14. Biochemical and structural characterization of cathepsin L-processed Ebola virus glycoprotein: implications for viral entry and immunogenicity. Hood CL, Abraham J, Boyington JC, Leung K, Kwong PD, Nabel GJ. J Virol 84 2972-2982 (2010)
  15. Mechanism of Binding to Ebola Virus Glycoprotein by the ZMapp, ZMAb, and MB-003 Cocktail Antibodies. Davidson E, Bryan C, Fong RH, Barnes T, Pfaff JM, Mabila M, Rucker JB, Doranz BJ. J Virol 89 10982-10992 (2015)
  16. The organisation of Ebola virus reveals a capacity for extensive, modular polyploidy. Beniac DR, Melito PL, Devarennes SL, Hiebert SL, Rabb MJ, Lamboo LL, Jones SM, Booth TF. PLoS One 7 e29608 (2012)
  17. Structural basis for Marburg virus neutralization by a cross-reactive human antibody. Hashiguchi T, Fusco ML, Bornholdt ZA, Lee JE, Flyak AI, Matsuoka R, Kohda D, Yanagi Y, Hammel M, Crowe JE, Saphire EO. Cell 160 904-912 (2015)
  18. Structure and function of the complete internal fusion loop from Ebolavirus glycoprotein 2. Gregory SM, Harada E, Liang B, Delos SE, White JM, Tamm LK. Proc Natl Acad Sci U S A 108 11211-11216 (2011)
  19. Structure of the cleavage-activated prefusion form of the parainfluenza virus 5 fusion protein. Welch BD, Liu Y, Kors CA, Leser GP, Jardetzky TS, Lamb RA. Proc Natl Acad Sci U S A 109 16672-16677 (2012)
  20. Pan-ebolavirus and Pan-filovirus Mouse Monoclonal Antibodies: Protection against Ebola and Sudan Viruses. Holtsberg FW, Shulenin S, Vu H, Howell KA, Patel SJ, Gunn B, Karim M, Lai JR, Frei JC, Nyakatura EK, Zeitlin L, Douglas R, Fusco ML, Froude JW, Saphire EO, Herbert AS, Wirchnianski AS, Lear-Rooney CM, Alter G, Dye JM, Glass PJ, Warfield KL, Aman MJ. J Virol 90 266-278 (2016)
  21. Molecular characterization of the monoclonal antibodies composing ZMAb: a protective cocktail against Ebola virus. Audet J, Wong G, Wang H, Lu G, Gao GF, Kobinger G, Qiu X. Sci Rep 4 6881 (2014)
  22. Comprehensive functional analysis of N-linked glycans on Ebola virus GP1. Lennemann NJ, Rhein BA, Ndungo E, Chandran K, Qiu X, Maury W. mBio 5 e00862-13 (2014)
  23. Structures of Ebola virus GP and sGP in complex with therapeutic antibodies. Pallesen J, Murin CD, de Val N, Cottrell CA, Hastie KM, Turner HL, Fusco ML, Flyak AI, Zeitlin L, Crowe JE, Andersen KG, Saphire EO, Ward AB. Nat Microbiol 1 16128 (2016)
  24. Discovery of an antibody for pan-ebolavirus therapy. Furuyama W, Marzi A, Nanbo A, Haddock E, Maruyama J, Miyamoto H, Igarashi M, Yoshida R, Noyori O, Feldmann H, Takada A. Sci Rep 6 20514 (2016)
  25. Antibody Treatment of Ebola and Sudan Virus Infection via a Uniquely Exposed Epitope within the Glycoprotein Receptor-Binding Site. Howell KA, Qiu X, Brannan JM, Bryan C, Davidson E, Holtsberg FW, Wec AZ, Shulenin S, Biggins JE, Douglas R, Enterlein SG, Turner HL, Pallesen J, Murin CD, He S, Kroeker A, Vu H, Herbert AS, Fusco ML, Nyakatura EK, Lai JR, Keck ZY, Foung SKH, Saphire EO, Zeitlin L, Ward AB, Chandran K, Doranz BJ, Kobinger GP, Dye JM, Aman MJ. Cell Rep 15 1514-1526 (2016)
  26. Host-Primed Ebola Virus GP Exposes a Hydrophobic NPC1 Receptor-Binding Pocket, Revealing a Target for Broadly Neutralizing Antibodies. Bornholdt ZA, Ndungo E, Fusco ML, Bale S, Flyak AI, Crowe JE, Chandran K, Saphire EO. mBio 7 e02154-15 (2016)
  27. Ebola virus glycoprotein needs an additional trigger, beyond proteolytic priming for membrane fusion. Bale S, Liu T, Li S, Wang Y, Abelson D, Fusco M, Woods VL, Saphire EO. PLoS Negl Trop Dis 5 e1395 (2011)
  28. Filovirus receptor NPC1 contributes to species-specific patterns of ebolavirus susceptibility in bats. Ng M, Ndungo E, Kaczmarek ME, Herbert AS, Binger T, Kuehne AI, Jangra RK, Hawkins JA, Gifford RJ, Biswas R, Demogines A, James RM, Yu M, Brummelkamp TR, Drosten C, Wang LF, Kuhn JH, Müller MA, Dye JM, Sawyer SL, Chandran K. Elife 4 (2015)
  29. Macaque Monoclonal Antibodies Targeting Novel Conserved Epitopes within Filovirus Glycoprotein. Keck ZY, Enterlein SG, Howell KA, Vu H, Shulenin S, Warfield KL, Froude JW, Araghi N, Douglas R, Biggins J, Lear-Rooney CM, Wirchnianski AS, Lau P, Wang Y, Herbert AS, Dye JM, Glass PJ, Holtsberg FW, Foung SK, Aman MJ. J Virol 90 279-291 (2016)
  30. Cooperativity Enables Non-neutralizing Antibodies to Neutralize Ebolavirus. Howell KA, Brannan JM, Bryan C, McNeal A, Davidson E, Turner HL, Vu H, Shulenin S, He S, Kuehne A, Herbert AS, Qiu X, Doranz BJ, Holtsberg FW, Ward AB, Dye JM, Aman MJ. Cell Rep 19 413-424 (2017)
  31. Identification of continuous human B-cell epitopes in the VP35, VP40, nucleoprotein and glycoprotein of Ebola virus. Becquart P, Mahlakõiv T, Nkoghe D, Leroy EM. PLoS One 9 e96360 (2014)
  32. Spatial localization of the Ebola virus glycoprotein mucin-like domain determined by cryo-electron tomography. Tran EE, Simmons JA, Bartesaghi A, Shoemaker CJ, Nelson E, White JM, Subramaniam S. J Virol 88 10958-10962 (2014)
  33. Ebola virus genome plasticity as a marker of its passaging history: a comparison of in vitro passaging to non-human primate infection. Kugelman JR, Lee MS, Rossi CA, McCarthy SE, Radoshitzky SR, Dye JM, Hensley LE, Honko A, Kuhn JH, Jahrling PB, Warren TK, Whitehouse CA, Bavari S, Palacios G. PLoS One 7 e50316 (2012)
  34. Different potential of C-type lectin-mediated entry between Marburg virus strains. Matsuno K, Kishida N, Usami K, Igarashi M, Yoshida R, Nakayama E, Shimojima M, Feldmann H, Irimura T, Kawaoka Y, Takada A. J Virol 84 5140-5147 (2010)
  35. A novel membrane fusion protein family in Flaviviridae? Li Y, Modis Y. Trends Microbiol 22 176-182 (2014)
  36. Potent neutralizing monoclonal antibodies against Ebola virus infection. Zhang Q, Gui M, Niu X, He S, Wang R, Feng Y, Kroeker A, Zuo Y, Wang H, Wang Y, Li J, Li C, Shi Y, Shi X, Gao GF, Xiang Y, Qiu X, Chen L, Zhang L. Sci Rep 6 25856 (2016)
  37. Broadly neutralizing antibodies from human survivors target a conserved site in the Ebola virus glycoprotein HR2-MPER region. Flyak AI, Kuzmina N, Murin CD, Bryan C, Davidson E, Gilchuk P, Gulka CP, Ilinykh PA, Shen X, Huang K, Ramanathan P, Turner H, Fusco ML, Lampley R, Kose N, King H, Sapparapu G, Doranz BJ, Ksiazek TG, Wright DW, Saphire EO, Ward AB, Bukreyev A, Crowe JE. Nat Microbiol 3 670-677 (2018)
  38. Structure of the Ebola virus glycoprotein spike within the virion envelope at 11 Å resolution. Beniac DR, Booth TF. Sci Rep 7 46374 (2017)
  39. Structure of glycosylated NPC1 luminal domain C reveals insights into NPC2 and Ebola virus interactions. Zhao Y, Ren J, Harlos K, Stuart DI. FEBS Lett 590 605-612 (2016)
  40. Two synthetic antibodies that recognize and neutralize distinct proteolytic forms of the ebola virus envelope glycoprotein. Koellhoffer JF, Chen G, Sandesara RG, Bale S, Saphire EO, Chandran K, Sidhu SS, Lai JR. Chembiochem 13 2549-2557 (2012)
  41. A fusion-inhibiting peptide against Rift Valley fever virus inhibits multiple, diverse viruses. Koehler JW, Smith JM, Ripoll DR, Spik KW, Taylor SL, Badger CV, Grant RJ, Ogg MM, Wallqvist A, Guttieri MC, Garry RF, Schmaljohn CS. PLoS Negl Trop Dis 7 e2430 (2013)
  42. Ebolavirus is evolving but not changing: No evidence for functional change in EBOV from 1976 to the 2014 outbreak. Olabode AS, Jiang X, Robertson DL, Lovell SC. Virology 482 202-207 (2015)
  43. Mapping of Ebolavirus Neutralization by Monoclonal Antibodies in the ZMapp Cocktail Using Cryo-Electron Tomography and Studies of Cellular Entry. Tran EE, Nelson EA, Bonagiri P, Simmons JA, Shoemaker CJ, Schmaljohn CS, Kobinger GP, Zeitlin L, Subramaniam S, White JM. J Virol 90 7618-7627 (2016)
  44. Bispecific Antibody Affords Complete Post-Exposure Protection of Mice from Both Ebola (Zaire) and Sudan Viruses. Frei JC, Nyakatura EK, Zak SE, Bakken RR, Chandran K, Dye JM, Lai JR. Sci Rep 6 19193 (2016)
  45. Chemical and Structural Aspects of Ebola Virus Entry Inhibitors. Nyakatura EK, Frei JC, Lai JR. ACS Infect Dis 1 42-52 (2015)
  46. Combating Ebola with Repurposed Therapeutics Using the CANDO Platform. Chopra G, Chopra G, Kaushik S, Elkin PL, Samudrala R. Molecules 21 (2016)
  47. Conserved differences in protein sequence determine the human pathogenicity of Ebolaviruses. Pappalardo M, Juliá M, Howard MJ, Rossman JS, Michaelis M, Wass MN. Sci Rep 6 23743 (2016)
  48. Techniques and tactics used in determining the structure of the trimeric ebolavirus glycoprotein. Lee JE, Fusco ML, Abelson DM, Hessell AJ, Burton DR, Saphire EO. Acta Crystallogr D Biol Crystallogr 65 1162-1180 (2009)
  49. Structure-Based Design of Prefusion-Stabilized Filovirus Glycoprotein Trimers. Rutten L, Gilman MSA, Blokland S, Juraszek J, McLellan JS, Langedijk JPM. Cell Rep 30 4540-4550.e3 (2020)
  50. Initiating a watch list for Ebola virus antibody escape mutations. Miller CR, Johnson EL, Burke AZ, Martin KP, Miura TA, Wichman HA, Brown CJ, Ytreberg FM. PeerJ 4 e1674 (2016)
  51. In silico analysis suggests interaction between Ebola virus and the extracellular matrix. Veljkovic V, Glisic S, Muller CP, Scotch M, Branch DR, Perovic VR, Sencanski M, Veljkovic N, Colombatti A. Front Microbiol 6 135 (2015)
  52. Longitudinal Human Antibody Repertoire against Complete Viral Proteome from Ebola Virus Survivor Reveals Protective Sites for Vaccine Design. Khurana S, Ravichandran S, Hahn M, Coyle EM, Stonier SW, Zak SE, Kindrachuk J, Davey RT, Dye JM, Chertow DS. Cell Host Microbe 27 262-276.e4 (2020)
  53. Vesicular Stomatitis Virus Pseudotyped with Ebola Virus Glycoprotein Serves as a Protective, Noninfectious Vaccine against Ebola Virus Challenge in Mice. Lennemann NJ, Herbert AS, Brouillette R, Rhein B, Bakken RA, Perschbacher KJ, Cooney AL, Miller-Hunt CL, Ten Eyck P, Biggins J, Olinger G, Dye JM, Maury W. J Virol 91 (2017)
  54. A Single Residue in Ebola Virus Receptor NPC1 Influences Cellular Host Range in Reptiles. Ndungo E, Herbert AS, Raaben M, Obernosterer G, Biswas R, Miller EH, Wirchnianski AS, Carette JE, Brummelkamp TR, Whelan SP, Dye JM, Chandran K. mSphere 1 (2016)
  55. Receptor Activation of HIV-1 Env Leads to Asymmetric Exposure of the gp41 Trimer. Khasnis MD, Halkidis K, Bhardwaj A, Root MJ. PLoS Pathog 12 e1006098 (2016)
  56. The Role of Conserved N-Linked Glycans on Ebola Virus Glycoprotein 2. Lennemann NJ, Walkner M, Berkebile AR, Patel N, Maury W. J Infect Dis 212 Suppl 2 S204-9 (2015)
  57. Predictive and comparative analysis of Ebolavirus proteins. Cong Q, Pei J, Grishin NV. Cell Cycle 14 2785-2797 (2015)
  58. Structural basis for broad neutralization of ebolaviruses by an antibody targeting the glycoprotein fusion loop. Janus BM, van Dyk N, Zhao X, Howell KA, Soto C, Aman MJ, Li Y, Fuerst TR, Ofek G. Nat Commun 9 3934 (2018)
  59. Both Epistasis and Diversifying Selection Drive the Structural Evolution of the Ebola Virus Glycoprotein Mucin-Like Domain. Ibeh N, Nshogozabahizi JC, Aris-Brosou S. J Virol 90 5475-5484 (2016)
  60. Characterization of Influenza Virus Pseudotyped with Ebolavirus Glycoprotein. Xiao JH, Rijal P, Schimanski L, Tharkeshwar AK, Wright E, Annaert W, Townsend A. J Virol 92 (2018)
  61. Species-Specific Evolution of Ebola Virus during Replication in Human and Bat Cells. Whitfield ZJ, Prasad AN, Ronk AJ, Kuzmin IV, Ilinykh PA, Andino R, Bukreyev A. Cell Rep 32 108028 (2020)
  62. Computational analysis of envelope glycoproteins from diverse geographical isolates of bovine leukemia virus identifies highly conserved peptide motifs. Pluta A, Albritton LM, Rola-Łuszczak M, Kuźmak J. Retrovirology 15 2 (2018)
  63. Growth-Adaptive Mutations in the Ebola Virus Makona Glycoprotein Alter Different Steps in the Virus Entry Pathway. Ruedas JB, Arnold CE, Palacios G, Connor JH. J Virol 92 (2018)
  64. Conservancy of mAb Epitopes in Ebolavirus Glycoproteins of Previous and 2014 Outbreaks. Ponomarenko J, Vaughan K, Sette A, Maurer-Stroh S. PLoS Curr 6 (2014)
  65. An inter-residue network model to identify mutational-constrained regions on the Ebola coat glycoprotein. Quinlan DS, Raman R, Tharakaraman K, Subramanian V, Del Hierro G, Sasisekharan R. Sci Rep 7 45886 (2017)
  66. Characterization of Antigenic MHC-Class-I-Restricted T Cell Epitopes in the Glycoprotein of Ebolavirus. Powlson J, Wright D, Zeltina A, Giza M, Nielsen M, Rampling T, Venkatrakaman N, Bowden TA, Hill AVS, Ewer KJ. Cell Rep 29 2537-2545.e3 (2019)
  67. Characterizing alpha helical properties of Ebola viral proteins as potential targets for inhibition of alpha-helix mediated protein-protein interactions. Chakraborty S, Rao BJ, Asgeirsson B, Dandekar A. F1000Res 3 251 (2014)
  68. Global phosphoproteomic analysis of Ebola virions reveals a novel role for VP35 phosphorylation-dependent regulation of genome transcription. Ivanov A, Ramanathan P, Parry C, Ilinykh PA, Lin X, Petukhov M, Obukhov Y, Ammosova T, Amarasinghe GK, Bukreyev A, Nekhai S. Cell Mol Life Sci 77 2579-2603 (2020)
  69. Molecular modelling studies on adamantane-based Ebola virus GP-1 inhibitors using docking, pharmacophore and 3D-QSAR. Mali SN, Chaudhari HK. SAR QSAR Environ Res 30 161-180 (2019)
  70. Optimization of Methods for the Production and Refolding of Biologically Active Disulfide Bond-Rich Antibody Fragments in Microbial Hosts. Ban B, Sharma M, Shetty J. Antibodies (Basel) 9 E39 (2020)
  71. Structural Transition and Antibody Binding of EBOV GP and ZIKV E Proteins from Pre-Fusion to Fusion-Initiation State. Lappala A, Nishima W, Miner J, Fenimore P, Fischer W, Hraber P, Zhang M, McMahon B, Tung CS. Biomolecules 8 (2018)
  72. Glycan shield of the ebolavirus envelope glycoprotein GP. Peng W, Rayaprolu V, Parvate AD, Pronker MF, Hui S, Parekh D, Shaffer K, Yu X, Saphire EO, Snijder J. Commun Biol 5 785 (2022)
  73. Identity and validity of conserved B cell epitopes of filovirus glycoprotein: towards rapid diagnostic testing for Ebola and possibly Marburg virus disease. Babirye P, Musubika C, Kirimunda S, Downing R, Lutwama JJ, Mbidde EK, Weyer J, Paweska JT, Joloba ML, Wayengera M. BMC Infect Dis 18 498 (2018)
  74. Potent neutralizing monoclonal antibodies against Ebola virus isolated from vaccinated donors. Fan P, Chi X, Liu G, Zhang G, Chen Z, Liu Y, Fang T, Li J, Banadyga L, He S, Yu C, Qiu X, Chen W. MAbs 12 1742457 (2020)
  75. Prominent Neutralizing Antibody Response Targeting the Ebolavirus Glycoprotein Subunit Interface Elicited by Immunization. Wang Y, Howell KA, Brannan J, Agans KN, Turner HL, Wirchnianski AS, Kailasan S, Fusco M, Galkin A, Chiang CI, Zhao X, Saphire EO, Chandran K, Ward AB, Dye JM, Aman MJ, Geisbert TW, Li Y. J Virol (2021)
  76. Activation of Toll-like receptor 4 by Ebola virus-shed glycoprotein is direct and requires the internal fusion loop but not glycosylation. Scherm MJ, Gangloff M, Gay NJ. Cell Rep 41 111562 (2022)
  77. Combinatorial peptide-based epitope mapping from Ebola virus DNA vaccines and infections reveals residue-level determinants of antibody binding. Ripoll DR, Mitchell DAJ, Dupuy LC, Wallqvist A, Schmaljohn C, Chaudhury S. Hum Vaccin Immunother 13 2953-2966 (2017)
  78. Deep-Time Structural Evolution of Retroviral and Filoviral Surface Envelope Proteins. Hötzel I. J Virol 96 e0006322 (2022)
  79. New Perspectives on Ebola Virus Evolution. Brown CJ, Quates CJ, Mirabzadeh CA, Miller CR, Wichman HA, Miura TA, Ytreberg FM. PLoS One 11 e0160410 (2016)
  80. Rapid exploration of the epitope coverage produced by an Ebola survivor to guide the discovery of therapeutic antibody cocktails. Yuan TZ, Lujan Hernandez AG, Keane E, Liu Q, Axelrod F, Kailasan S, Noonan-Shueh M, Aman MJ, Sato AK, Abdiche YN. Antib Ther 3 167-178 (2020)
  81. Structure of the Inmazeb cocktail and resistance to Ebola virus escape. Rayaprolu V, Fulton BO, Rafique A, Arturo E, Williams D, Hariharan C, Callaway H, Parvate A, Schendel SL, Parekh D, Hui S, Shaffer K, Pascal KE, Wloga E, Giordano S, Negron N, Ni M, Copin R, Atwal GS, Franklin M, Boytz RM, Donahue C, Davey R, Baum A, Kyratsous CA, Saphire EO. Cell Host Microbe 31 260-272.e7 (2023)


Reviews citing this publication (79)

  1. Viral membrane fusion. Harrison SC. Virology 479-480 498-507 (2015)
  2. Structure unifies the viral universe. Abrescia NG, Bamford DH, Grimes JM, Stuart DI. Annu Rev Biochem 81 795-822 (2012)
  3. Fusion of Enveloped Viruses in Endosomes. White JM, Whittaker GR. Traffic 17 593-614 (2016)
  4. Coronavirus Spike Protein and Tropism Changes. Hulswit RJ, de Haan CA, Bosch BJ. Adv Virus Res 96 29-57 (2016)
  5. The HIV-1 envelope glycoprotein structure: nailing down a moving target. Ward AB, Wilson IA. Immunol Rev 275 21-32 (2017)
  6. Exploitation of glycosylation in enveloped virus pathobiology. Watanabe Y, Bowden TA, Wilson IA, Crispin M. Biochim Biophys Acta Gen Subj 1863 1480-1497 (2019)
  7. Passive immunotherapy of viral infections: 'super-antibodies' enter the fray. Walker LM, Burton DR. Nat Rev Immunol 18 297-308 (2018)
  8. HIV-1 and influenza antibodies: seeing antigens in new ways. Kwong PD, Wilson IA. Nat Immunol 10 573-578 (2009)
  9. Common Features of Enveloped Viruses and Implications for Immunogen Design for Next-Generation Vaccines. Rey FA, Lok SM. Cell 172 1319-1334 (2018)
  10. Cell entry of enveloped viruses. Plemper RK. Curr Opin Virol 1 92-100 (2011)
  11. HIV-1 envelope glycoprotein structure. Merk A, Subramaniam S. Curr Opin Struct Biol 23 268-276 (2013)
  12. Antibody responses to viral infections: a structural perspective across three different enveloped viruses. Murin CD, Wilson IA, Ward AB. Nat Microbiol 4 734-747 (2019)
  13. Ebola virus entry: a curious and complex series of events. Moller-Tank S, Maury W. PLoS Pathog 11 e1004731 (2015)
  14. Targeting host-derived glycans on enveloped viruses for antibody-based vaccine design. Crispin M, Doores KJ. Curr Opin Virol 11 63-69 (2015)
  15. Antibody-mediated protection against Ebola virus. Saphire EO, Schendel SL, Gunn BM, Milligan JC, Alter G. Nat Immunol 19 1169-1178 (2018)
  16. Herpesvirus gB: A Finely Tuned Fusion Machine. Cooper RS, Heldwein EE. Viruses 7 6552-6569 (2015)
  17. Timing is everything: Fine-tuned molecular machines orchestrate paramyxovirus entry. Bose S, Jardetzky TS, Lamb RA. Virology 479-480 518-531 (2015)
  18. The multiple roles of sGP in Ebola pathogenesis. de La Vega MA, Wong G, Kobinger GP, Qiu X. Viral Immunol 28 3-9 (2015)
  19. The three lives of viral fusion peptides. Apellániz B, Huarte N, Largo E, Nieva JL. Chem Phys Lipids 181 40-55 (2014)
  20. Cell entry of enveloped viruses. Cosset FL, Lavillette D. Adv Genet 73 121-183 (2011)
  21. Membrane binding and bending in Ebola VP40 assembly and egress. Stahelin RV. Front Microbiol 5 300 (2014)
  22. Virion Glycoprotein-Mediated Immune Evasion by Human Cytomegalovirus: a Sticky Virus Makes a Slick Getaway. Gardner TJ, Tortorella D. Microbiol Mol Biol Rev 80 663-677 (2016)
  23. An update on the use of antibodies against the filoviruses. Saphire EO. Immunotherapy 5 1221-1233 (2013)
  24. Discovery of protective B-cell epitopes for development of antimicrobial vaccines and antibody therapeutics. Sharon J, Rynkiewicz MJ, Lu Z, Yang CY. Immunology 142 1-23 (2014)
  25. Ebolavirus comparative genomics. Jun SR, Leuze MR, Nookaew I, Uberbacher EC, Land M, Zhang Q, Wanchai V, Chai J, Nielsen M, Trolle T, Lund O, Buzard GS, Pedersen TD, Wassenaar TM, Ussery DW. FEMS Microbiol Rev 39 764-778 (2015)
  26. Expression of recombinant glycoproteins in mammalian cells: towards an integrative approach to structural biology. Aricescu AR, Owens RJ. Curr Opin Struct Biol 23 345-356 (2013)
  27. Development of novel entry inhibitors targeting emerging viruses. Zhou Y, Simmons G. Expert Rev Anti Infect Ther 10 1129-1138 (2012)
  28. Human monoclonal antibodies as candidate therapeutics against emerging viruses. Jin Y, Lei C, Hu D, Dimitrov DS, Ying T. Front Med 11 462-470 (2017)
  29. Plant-produced candidate countermeasures against emerging and reemerging infections and bioterror agents. Streatfield SJ, Kushnir N, Yusibov V. Plant Biotechnol J 13 1136-1159 (2015)
  30. Advances in Designing and Developing Vaccines, Drugs, and Therapies to Counter Ebola Virus. Dhama K, Karthik K, Khandia R, Chakraborty S, Munjal A, Latheef SK, Kumar D, Ramakrishnan MA, Malik YS, Singh R, Malik SVS, Singh RK, Chaicumpa W. Front Immunol 9 1803 (2018)
  31. Development of therapeutics for treatment of Ebola virus infection. Li H, Ying T, Yu F, Lu L, Jiang S. Microbes Infect 17 109-117 (2015)
  32. Ebola Virus Entry: From Molecular Characterization to Drug Discovery. Salata C, Calistri A, Alvisi G, Celestino M, Parolin C, Palù G. Viruses 11 (2019)
  33. Conformational plasticity of the Ebola virus matrix protein. Radzimanowski J, Effantin G, Weissenhorn W. Protein Sci 23 1519-1527 (2014)
  34. Host cell factors in filovirus entry: novel players, new insights. Hofmann-Winkler H, Kaup F, Pöhlmann S. Viruses 4 3336-3362 (2012)
  35. Stabilizing HIV-1 envelope glycoprotein trimers to induce neutralizing antibodies. Torrents de la Peña A, Sanders RW. Retrovirology 15 63 (2018)
  36. The role of cysteine proteinases and their inhibitors in the host-pathogen cross talk. Kopitar-Jerala N. Curr Protein Pept Sci 13 767-775 (2012)
  37. Strategies in Ebola virus disease (EVD) diagnostics at the point of care. Coarsey CT, Esiobu N, Narayanan R, Pavlovic M, Shafiee H, Asghar W. Crit Rev Microbiol 43 779-798 (2017)
  38. Development of vaccines for prevention of Ebola virus infection. Ye L, Yang C. Microbes Infect 17 98-108 (2015)
  39. Antibody Production in Plants and Green Algae. Yusibov V, Kushnir N, Streatfield SJ. Annu Rev Plant Biol 67 669-701 (2016)
  40. Molecular mechanisms of Ebola pathogenesis. Rivera A, Messaoudi I. J Leukoc Biol 100 889-904 (2016)
  41. Hunting Viral Receptors Using Haploid Cells. Pillay S, Carette JE. Annu Rev Virol 2 219-239 (2015)
  42. Surfactant Proteins A and D: Trimerized Innate Immunity Proteins with an Affinity for Viral Fusion Proteins. Watson A, Phipps MJS, Clark HW, Skylaris CK, Madsen J. J Innate Immun 11 13-28 (2019)
  43. Antibodies to combat viral infections: development strategies and progress. Pantaleo G, Correia B, Fenwick C, Joo VS, Perez L. Nat Rev Drug Discov 21 676-696 (2022)
  44. Immune evasion in ebolavirus infections. Audet J, Kobinger GP. Viral Immunol 28 10-18 (2015)
  45. Viral glycoproteomes: technologies for characterization and outlook for vaccine design. Bagdonaite I, Vakhrushev SY, Joshi HJ, Wandall HH. FEBS Lett 592 3898-3920 (2018)
  46. Anti-Ebola therapies based on monoclonal antibodies: current state and challenges ahead. González-González E, Alvarez MM, Márquez-Ipiña AR, Trujillo-de Santiago G, Rodríguez-Martínez LM, Annabi N, Khademhosseini A, Khademhosseini A. Crit Rev Biotechnol 37 53-68 (2017)
  47. The roles of ebolavirus glycoproteins in viral pathogenesis. Ning YJ, Deng F, Hu Z, Wang H. Virol Sin 32 3-15 (2017)
  48. Therapeutics for filovirus infection: traditional approaches and progress towards in silico drug design. Shurtleff AC, Nguyen TL, Kingery DA, Bavari S. Expert Opin Drug Discov 7 935-954 (2012)
  49. Human monoclonal antibodies as candidate therapeutics against emerging viruses and HIV-1. Zhu Z, Prabakaran P, Chen W, Broder CC, Gong R, Dimitrov DS. Virol Sin 28 71-80 (2013)
  50. The structural basis for filovirus neutralization by monoclonal antibodies. King LB, West BR, Schendel SL, Saphire EO. Curr Opin Immunol 53 196-202 (2018)
  51. Cyanobacterial lectins characteristics and their role as antiviral agents. Singh RS, Walia AK, Khattar JS, Singh DP, Kennedy JF. Int J Biol Macromol 102 475-496 (2017)
  52. Ebola virus: A gap in drug design and discovery - experimental and computational perspective. Balmith M, Faya M, Soliman ME. Chem Biol Drug Des 89 297-308 (2017)
  53. Endocytic pathways involved in filovirus entry: advances, implications and future directions. Bhattacharyya S, Mulherkar N, Chandran K. Viruses 4 3647-3664 (2012)
  54. Structure and working of viral fusion machinery. Albertini A, Bressanelli S, Lepault J, Gaudin Y. Curr Top Membr 68 49-80 (2011)
  55. Ebola virus disease: an update for anesthesiologists and intensivists. Funk DJ, Kumar A. Can J Anaesth 62 80-91 (2015)
  56. Emerging zoonotic viruses: new lessons on receptor and entry mechanisms. Gerlier D. Curr Opin Virol 1 27-34 (2011)
  57. The lifecycle of the Ebola virus in host cells. Yu DS, Weng TH, Wu XX, Wang FXC, Lu XY, Wu HB, Wu NP, Li LJ, Yao HP. Oncotarget 8 55750-55759 (2017)
  58. Achieving cross-reactivity with pan-ebolavirus antibodies. King LB, Milligan JC, West BR, Schendel SL, Ollmann Saphire E. Curr Opin Virol 34 140-148 (2019)
  59. Filovirus entry. Simmons G. Adv Exp Med Biol 790 83-94 (2013)
  60. Vaccines for the Paramyxoviruses and Pneumoviruses: Successes, Candidates, and Hurdles. Russell CJ, Simões EAF, Hurwitz JL. Viral Immunol 31 133-141 (2018)
  61. Dynamic Viral Glycoprotein Machines: Approaches for Probing Transient States That Drive Membrane Fusion. Garcia NK, Lee KK. Viruses 8 (2016)
  62. Ebola virus outbreak, updates on current therapeutic strategies. Elshabrawy HA, Erickson TB, Prabhakar BS. Rev Med Virol 25 241-253 (2015)
  63. New Biophysical Approaches Reveal the Dynamics and Mechanics of Type I Viral Fusion Machinery and Their Interplay with Membranes. Benhaim MA, Lee KK. Viruses 12 (2020)
  64. Dendritic Cells/Macrophages-Targeting Feature of Ebola Glycoprotein and its Potential as Immunological Facilitator for Antiviral Vaccine Approach. Olukitibi TA, Ao Z, Mahmoudi M, Kobinger GA, Yao X. Microorganisms 7 (2019)
  65. Mucins and Pathogenic Mucin-Like Molecules Are Immunomodulators During Infection and Targets for Diagnostics and Vaccines. Pinzón Martín S, Seeberger PH, Varón Silva D. Front Chem 7 710 (2019)
  66. Naïve Human Antibody Libraries for Infectious Diseases. Chan SK, Rahumatullah A, Lai JY, Lim TS. Adv Exp Med Biol 1053 35-59 (2017)
  67. Structural and Functional Aspects of Ebola Virus Proteins. Jain S, Martynova E, Rizvanov A, Khaiboullina S, Baranwal M. Pathogens 10 1330 (2021)
  68. Proteomics-based mass spectrometry profiling of SARS-CoV-2 infection from human nasopharyngeal samples. Chatterjee S, Zaia J. Mass Spectrom Rev e21813 (2022)
  69. Pseudotyped Vesicular Stomatitis Virus-Severe Acute Respiratory Syndrome-Coronavirus-2 Spike for the Study of Variants, Vaccines, and Therapeutics Against Coronavirus Disease 2019. Salazar-García M, Acosta-Contreras S, Rodríguez-Martínez G, Cruz-Rangel A, Flores-Alanis A, Patiño-López G, Luna-Pineda VM. Front Microbiol 12 817200 (2021)
  70. Algal and Cyanobacterial Lectins and Their Antimicrobial Properties. Fernández Romero JA, Paglini MG, Priano C, Koroch A, Rodríguez Y, Sailer J, Teleshova N. Mar Drugs 19 687 (2021)
  71. Development and Structural Analysis of Antibody Therapeutics for Filoviruses. Yu X, Saphire EO. Pathogens 11 374 (2022)
  72. Ebanga™: The most recent FDA-approved drug for treating Ebola. Taki E, Ghanavati R, Navidifar T, Dashtbin S, Heidary M, Moghadamnia M. Front Pharmacol 14 1083429 (2023)
  73. Filovirus Neutralising Antibodies: Mechanisms of Action and Therapeutic Application. Hargreaves A, Brady C, Mellors J, Tipton T, Carroll MW, Longet S. Pathogens 10 (2021)
  74. Glycans in Virus-Host Interactions: A Structural Perspective. Miller NL, Clark T, Raman R, Sasisekharan R. Front Mol Biosci 8 666756 (2021)
  75. Immune correlates of protection for SARS-CoV-2, Ebola and Nipah virus infection. Escudero-Pérez B, Lawrence P, Castillo-Olivares J. Front Immunol 14 1156758 (2023)
  76. Modulating Neurological Complications of Emerging Infectious Diseases: Mechanistic Approaches to Candidate Phytochemicals. Fakhri S, Mohammadi Pour P, Piri S, Farzaei MH, Echeverría J. Front Pharmacol 12 742146 (2021)
  77. Review: Insights on Current FDA-Approved Monoclonal Antibodies Against Ebola Virus Infection. Tshiani Mbaya O, Mukumbayi P, Mulangu S. Front Immunol 12 721328 (2021)
  78. Single-Molecule FRET Imaging of Virus Spike-Host Interactions. Lu M. Viruses 13 (2021)
  79. Stabilisation of Viral Membrane Fusion Proteins in Prefusion Conformation by Structure-Based Design for Structure Determination and Vaccine Development. Ebel H, Benecke T, Vollmer B. Viruses 14 1816 (2022)

Articles citing this publication (297)

  1. Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Sui J, Hwang WC, Perez S, Wei G, Aird D, Chen LM, Santelli E, Stec B, Cadwell G, Ali M, Wan H, Murakami A, Yammanuru A, Han T, Cox NJ, Bankston LA, Donis RO, Liddington RC, Marasco WA. Nat Struct Mol Biol 16 265-273 (2009)
  2. A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. Corti D, Voss J, Gamblin SJ, Codoni G, Macagno A, Jarrossay D, Vachieri SG, Pinna D, Minola A, Vanzetta F, Silacci C, Fernandez-Rodriguez BM, Agatic G, Bianchi S, Giacchetto-Sasselli I, Calder L, Sallusto F, Collins P, Haire LF, Temperton N, Langedijk JP, Skehel JJ, Lanzavecchia A. Science 333 850-856 (2011)
  3. Crystal structure of a soluble cleaved HIV-1 envelope trimer. Julien JP, Cupo A, Sok D, Stanfield RL, Lyumkis D, Deller MC, Klasse PJ, Burton DR, Sanders RW, Moore JP, Ward AB, Wilson IA. Science 342 1477-1483 (2013)
  4. Activation of the SARS coronavirus spike protein via sequential proteolytic cleavage at two distinct sites. Belouzard S, Chu VC, Whittaker GR. Proc Natl Acad Sci U S A 106 5871-5876 (2009)
  5. Small molecule inhibitors reveal Niemann-Pick C1 is essential for Ebola virus infection. Côté M, Misasi J, Ren T, Bruchez A, Lee K, Filone CM, Hensley L, Li Q, Ory D, Chandran K, Cunningham J. Nature 477 344-348 (2011)
  6. Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody. McLellan JS, Chen M, Leung S, Graepel KW, Du X, Yang Y, Zhou T, Baxa U, Yasuda E, Beaumont T, Kumar A, Modjarrad K, Zheng Z, Zhao M, Xia N, Kwong PD, Graham BS. Science 340 1113-1117 (2013)
  7. Pre-fusion structure of a human coronavirus spike protein. Kirchdoerfer RN, Cottrell CA, Wang N, Pallesen J, Yassine HM, Turner HL, Corbett KS, Graham BS, McLellan JS, Ward AB. Nature 531 118-121 (2016)
  8. Tetherin-mediated restriction of filovirus budding is antagonized by the Ebola glycoprotein. Kaletsky RL, Francica JR, Agrawal-Gamse C, Bates P. Proc Natl Acad Sci U S A 106 2886-2891 (2009)
  9. Broadly neutralizing HIV antibodies define a glycan-dependent epitope on the prefusion conformation of gp41 on cleaved envelope trimers. Falkowska E, Le KM, Ramos A, Doores KJ, Lee JH, Blattner C, Ramirez A, Derking R, van Gils MJ, Liang CH, Mcbride R, von Bredow B, Shivatare SS, Wu CY, Chan-Hui PY, Liu Y, Feizi T, Zwick MB, Koff WC, Seaman MS, Swiderek K, Moore JP, Evans D, Paulson JC, Wong CH, Ward AB, Wilson IA, Sanders RW, Poignard P, Burton DR. Immunity 40 657-668 (2014)
  10. Ebolavirus is internalized into host cells via macropinocytosis in a viral glycoprotein-dependent manner. Nanbo A, Imai M, Watanabe S, Noda T, Takahashi K, Neumann G, Halfmann P, Kawaoka Y. PLoS Pathog 6 e1001121 (2010)
  11. Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody. Corti D, Misasi J, Mulangu S, Stanley DA, Kanekiyo M, Wollen S, Ploquin A, Doria-Rose NA, Staupe RP, Bailey M, Shi W, Choe M, Marcus H, Thompson EA, Cagigi A, Silacci C, Fernandez-Rodriguez B, Perez L, Sallusto F, Vanzetta F, Agatic G, Cameroni E, Kisalu N, Gordon I, Ledgerwood JE, Mascola JR, Graham BS, Muyembe-Tamfun JJ, Trefry JC, Lanzavecchia A, Sullivan NJ. Science 351 1339-1342 (2016)
  12. Unexpected inheritance: multiple integrations of ancient bornavirus and ebolavirus/marburgvirus sequences in vertebrate genomes. Belyi VA, Levine AJ, Skalka AM. PLoS Pathog 6 e1001030 (2010)
  13. Ebolavirus glycoprotein structure and mechanism of entry. Lee JE, Saphire EO. Future Virol 4 621-635 (2009)
  14. Trimeric HIV-1 glycoprotein gp140 immunogens and native HIV-1 envelope glycoproteins display the same closed and open quaternary molecular architectures. Harris A, Borgnia MJ, Shi D, Bartesaghi A, He H, Pejchal R, Kang YK, Depetris R, Marozsan AJ, Sanders RW, Klasse PJ, Milne JL, Wilson IA, Olson WC, Moore JP, Subramaniam S. Proc Natl Acad Sci U S A 108 11440-11445 (2011)
  15. Structural Insights into the Niemann-Pick C1 (NPC1)-Mediated Cholesterol Transfer and Ebola Infection. Gong X, Qian H, Zhou X, Wu J, Wan T, Cao P, Huang W, Zhao X, Wang X, Wang P, Shi Y, Gao GF, Zhou Q, Yan N. Cell 165 1467-1478 (2016)
  16. Characterization of a highly conserved domain within the severe acute respiratory syndrome coronavirus spike protein S2 domain with characteristics of a viral fusion peptide. Madu IG, Roth SL, Belouzard S, Whittaker GR. J Virol 83 7411-7421 (2009)
  17. The primed ebolavirus glycoprotein (19-kilodalton GP1,2): sequence and residues critical for host cell binding. Dube D, Brecher MB, Delos SE, Rose SC, Park EW, Schornberg KL, Kuhn JH, White JM. J Virol 83 2883-2891 (2009)
  18. Antigenic subversion: a novel mechanism of host immune evasion by Ebola virus. Mohan GS, Li W, Ye L, Compans RW, Yang C. PLoS Pathog 8 e1003065 (2012)
  19. A shared structural solution for neutralizing ebolaviruses. Dias JM, Kuehne AI, Abelson DM, Bale S, Wong AC, Halfmann P, Muhammad MA, Fusco ML, Zak SE, Kang E, Kawaoka Y, Chandran K, Dye JM, Saphire EO. Nat Struct Mol Biol 18 1424-1427 (2011)
  20. Structural and molecular basis for Ebola virus neutralization by protective human antibodies. Misasi J, Gilman MS, Kanekiyo M, Gui M, Cagigi A, Mulangu S, Corti D, Ledgerwood JE, Lanzavecchia A, Cunningham J, Muyembe-Tamfun JJ, Baxa U, Graham BS, Xiang Y, Sullivan NJ, McLellan JS. Science 351 1343-1346 (2016)
  21. Cathepsin cleavage potentiates the Ebola virus glycoprotein to undergo a subsequent fusion-relevant conformational change. Brecher M, Schornberg KL, Delos SE, Fusco ML, Saphire EO, White JM. J Virol 86 364-372 (2012)
  22. Human Adaptation of Ebola Virus during the West African Outbreak. Urbanowicz RA, McClure CP, Sakuntabhai A, Sall AA, Kobinger G, Müller MA, Holmes EC, Rey FA, Simon-Loriere E, Ball JK. Cell 167 1079-1087.e5 (2016)
  23. Mechanism of human antibody-mediated neutralization of Marburg virus. Flyak AI, Ilinykh PA, Murin CD, Garron T, Shen X, Fusco ML, Hashiguchi T, Bornholdt ZA, Slaughter JC, Sapparapu G, Klages C, Ksiazek TG, Ward AB, Saphire EO, Bukreyev A, Crowe JE. Cell 160 893-903 (2015)
  24. Shed GP of Ebola virus triggers immune activation and increased vascular permeability. Escudero-Pérez B, Volchkova VA, Dolnik O, Lawrence P, Volchkov VE. PLoS Pathog 10 e1004509 (2014)
  25. Structural basis for antibody-mediated neutralization of Lassa virus. Hastie KM, Zandonatti MA, Kleinfelter LM, Heinrich ML, Rowland MM, Chandran K, Branco LM, Robinson JE, Garry RF, Saphire EO. Science 356 923-928 (2017)
  26. A Role for Fc Function in Therapeutic Monoclonal Antibody-Mediated Protection against Ebola Virus. Gunn BM, Yu WH, Karim MM, Brannan JM, Herbert AS, Wec AZ, Halfmann PJ, Fusco ML, Schendel SL, Gangavarapu K, Krause T, Qiu X, He S, Das J, Suscovich TJ, Lai J, Chandran K, Zeitlin L, Crowe JE, Lauffenburger D, Kawaoka Y, Kobinger GP, Andersen KG, Dye JM, Saphire EO, Alter G. Cell Host Microbe 24 221-233.e5 (2018)
  27. Demonstration of cross-protective vaccine immunity against an emerging pathogenic Ebolavirus Species. Hensley LE, Mulangu S, Asiedu C, Johnson J, Honko AN, Stanley D, Fabozzi G, Nichol ST, Ksiazek TG, Rollin PE, Wahl-Jensen V, Bailey M, Jahrling PB, Roederer M, Koup RA, Sullivan NJ. PLoS Pathog 6 e1000904 (2010)
  28. Immune parameters correlate with protection against ebola virus infection in rodents and nonhuman primates. Wong G, Richardson JS, Pillet S, Patel A, Qiu X, Alimonti J, Hogan J, Zhang Y, Takada A, Feldmann H, Kobinger GP. Sci Transl Med 4 158ra146 (2012)
  29. Steric shielding of surface epitopes and impaired immune recognition induced by the ebola virus glycoprotein. Francica JR, Varela-Rohena A, Medvec A, Plesa G, Riley JL, Bates P. PLoS Pathog 6 e1001098 (2010)
  30. Cryo-electron tomography of Marburg virus particles and their morphogenesis within infected cells. Bharat TA, Riches JD, Kolesnikova L, Welsch S, Krähling V, Davey N, Parsy ML, Becker S, Briggs JA. PLoS Biol 9 e1001196 (2011)
  31. Crystal Structure of the Human Cytomegalovirus Glycoprotein B. Burke HG, Heldwein EE. PLoS Pathog 11 e1005227 (2015)
  32. Filoviruses require endosomal cysteine proteases for entry but exhibit distinct protease preferences. Misasi J, Chandran K, Yang JY, Considine B, Filone CM, Côté M, Sullivan N, Fabozzi G, Hensley L, Cunningham J. J Virol 86 3284-3292 (2012)
  33. The Ebola virus glycoprotein mediates entry via a non-classical dynamin-dependent macropinocytic pathway. Mulherkar N, Raaben M, de la Torre JC, Whelan SP, Chandran K. Virology 419 72-83 (2011)
  34. Point mutation in the glycoprotein of lymphocytic choriomeningitis virus is necessary for receptor binding, dendritic cell infection, and long-term persistence. Sullivan BM, Emonet SF, Welch MJ, Lee AM, Campbell KP, de la Torre JC, Oldstone MB. Proc Natl Acad Sci U S A 108 2969-2974 (2011)
  35. A small-molecule oxocarbazate inhibitor of human cathepsin L blocks severe acute respiratory syndrome and ebola pseudotype virus infection into human embryonic kidney 293T cells. Shah PP, Wang T, Kaletsky RL, Myers MC, Purvis JE, Jing H, Huryn DM, Greenbaum DC, Smith AB, Bates P, Diamond SL. Mol Pharmacol 78 319-324 (2010)
  36. Expression of an immunogenic Ebola immune complex in Nicotiana benthamiana. Phoolcharoen W, Bhoo SH, Lai H, Ma J, Arntzen CJ, Chen Q, Mason HS. Plant Biotechnol J 9 807-816 (2011)
  37. Identification of a small-molecule entry inhibitor for filoviruses. Basu A, Li B, Mills DM, Panchal RG, Cardinale SC, Butler MM, Peet NP, Majgier-Baranowska H, Williams JD, Patel I, Moir DT, Bavari S, Ray R, Farzan MR, Rong L, Bowlin TL. J Virol 85 3106-3119 (2011)
  38. Most neutralizing human monoclonal antibodies target novel epitopes requiring both Lassa virus glycoprotein subunits. Robinson JE, Hastie KM, Cross RW, Yenni RE, Elliott DH, Rouelle JA, Kannadka CB, Smira AA, Garry CE, Bradley BT, Yu H, Shaffer JG, Boisen ML, Hartnett JN, Zandonatti MA, Rowland MM, Heinrich ML, Martínez-Sobrido L, Cheng B, de la Torre JC, Andersen KG, Goba A, Momoh M, Fullah M, Gbakie M, Kanneh L, Koroma VJ, Fonnie R, Jalloh SC, Kargbo B, Vandi MA, Gbetuwa M, Ikponmwosa O, Asogun DA, Okokhere PO, Follarin OA, Schieffelin JS, Pitts KR, Geisbert JB, Kulakoski PC, Wilson RB, Happi CT, Sabeti PC, Gevao SM, Khan SH, Grant DS, Geisbert TW, Saphire EO, Branco LM, Garry RF. Nat Commun 7 11544 (2016)
  39. Neutralizing epitopes of the SARS-CoV S-protein cluster independent of repertoire, antigen structure or mAb technology. Berry JD, Hay K, Rini JM, Yu M, Wang L, Plummer FA, Corbett CR, Andonov A. MAbs 2 53-66 (2010)
  40. Uncleaved prefusion-optimized gp140 trimers derived from analysis of HIV-1 envelope metastability. Kong L, He L, de Val N, Vora N, Morris CD, Azadnia P, Sok D, Zhou B, Burton DR, Ward AB, Wilson IA, Zhu J. Nat Commun 7 12040 (2016)
  41. Clinical Features of Patients With Ebola Virus Disease in Sierra Leone. Qin E, Bi J, Zhao M, Wang Y, Guo T, Yan T, Li Z, Sun J, Zhang J, Chen S, Wu Y, Li J, Zhong Y. Clin Infect Dis 61 491-495 (2015)
  42. Antibody-mediated neutralization of Ebola virus can occur by two distinct mechanisms. Shedlock DJ, Bailey MA, Popernack PM, Cunningham JM, Burton DR, Sullivan NJ. Virology 401 228-235 (2010)
  43. The spatio-temporal distribution dynamics of Ebola virus proteins and RNA in infected cells. Nanbo A, Watanabe S, Halfmann P, Kawaoka Y. Sci Rep 3 1206 (2013)
  44. Model Building and Refinement of a Natively Glycosylated HIV-1 Env Protein by High-Resolution Cryoelectron Microscopy. Lee JH, de Val N, Lyumkis D, Ward AB. Structure 23 1943-1951 (2015)
  45. Immunization-Elicited Broadly Protective Antibody Reveals Ebolavirus Fusion Loop as a Site of Vulnerability. Zhao X, Howell KA, He S, Brannan JM, Wec AZ, Davidson E, Turner HL, Chiang CI, Lei L, Fels JM, Vu H, Shulenin S, Turonis AN, Kuehne AI, Liu G, Ta M, Wang Y, Sundling C, Xiao Y, Spence JS, Doranz BJ, Holtsberg FW, Ward AB, Chandran K, Dye JM, Qiu X, Li Y, Aman MJ. Cell 169 891-904.e15 (2017)
  46. Ebolavirus glycoprotein GP masks both its own epitopes and the presence of cellular surface proteins. Reynard O, Borowiak M, Volchkova VA, Delpeut S, Mateo M, Volchkov VE. J Virol 83 9596-9601 (2009)
  47. Inactivated or live-attenuated bivalent vaccines that confer protection against rabies and Ebola viruses. Blaney JE, Wirblich C, Papaneri AB, Johnson RF, Myers CJ, Juelich TL, Holbrook MR, Freiberg AN, Bernbaum JG, Jahrling PB, Paragas J, Schnell MJ. J Virol 85 10605-10616 (2011)
  48. Longitudinal Analysis of the Human B Cell Response to Ebola Virus Infection. Davis CW, Jackson KJL, McElroy AK, Halfmann P, Huang J, Chennareddy C, Piper AE, Leung Y, Albariño CG, Crozier I, Ellebedy AH, Sidney J, Sette A, Yu T, Nielsen SCA, Goff AJ, Spiropoulou CF, Saphire EO, Cavet G, Kawaoka Y, Mehta AK, Glass PJ, Boyd SD, Ahmed R. Cell 177 1566-1582.e17 (2019)
  49. Current developments in Coot for macromolecular model building of Electron Cryo-microscopy and Crystallographic Data. Casañal A, Lohkamp B, Emsley P. Protein Sci 29 1069-1078 (2020)
  50. Development of Clinical-Stage Human Monoclonal Antibodies That Treat Advanced Ebola Virus Disease in Nonhuman Primates. Pascal KE, Dudgeon D, Trefry JC, Anantpadma M, Sakurai Y, Murin CD, Turner HL, Fairhurst J, Torres M, Rafique A, Yan Y, Badithe A, Yu K, Potocky T, Bixler SL, Chance TB, Pratt WD, Rossi FD, Shamblin JD, Wollen SE, Zelko JM, Carrion R, Worwa G, Staples HM, Burakov D, Babb R, Chen G, Martin J, Huang TT, Erlandson K, Willis MS, Armstrong K, Dreier TM, Ward AB, Davey RA, Pitt MLM, Lipsich L, Mason P, Olson W, Stahl N, Kyratsous CA. J Infect Dis 218 S612-S626 (2018)
  51. Crystal structure of HIV-1 primary receptor CD4 in complex with a potent antiviral antibody. Freeman MM, Seaman MS, Rits-Volloch S, Hong X, Kao CY, Ho DD, Chen B. Structure 18 1632-1641 (2010)
  52. Direct Visualization of Ebola Virus Fusion Triggering in the Endocytic Pathway. Spence JS, Krause TB, Mittler E, Jangra RK, Chandran K. mBio 7 e01857-15 (2016)
  53. Human antibody repertoire after VSV-Ebola vaccination identifies novel targets and virus-neutralizing IgM antibodies. Khurana S, Fuentes S, Coyle EM, Ravichandran S, Davey RT, Beigel JH. Nat Med 22 1439-1447 (2016)
  54. Emergence of Ebola Virus Escape Variants in Infected Nonhuman Primates Treated with the MB-003 Antibody Cocktail. Kugelman JR, Kugelman-Tonos J, Ladner JT, Pettit J, Keeton CM, Nagle ER, Garcia KY, Froude JW, Kuehne AI, Kuhn JH, Bavari S, Zeitlin L, Dye JM, Olinger GG, Sanchez-Lockhart M, Palacios GF. Cell Rep 12 2111-2120 (2015)
  55. Letter Filovirus RefSeq entries: evaluation and selection of filovirus type variants, type sequences, and names. Kuhn JH, Andersen KG, Bào Y, Bavari S, Becker S, Bennett RS, Bergman NH, Blinkova O, Bradfute S, Brister JR, Bukreyev A, Chandran K, Chepurnov AA, Davey RA, Dietzgen RG, Doggett NA, Dolnik O, Dye JM, Enterlein S, Fenimore PW, Formenty P, Freiberg AN, Garry RF, Garza NL, Gire SK, Gonzalez JP, Griffiths A, Happi CT, Hensley LE, Herbert AS, Hevey MC, Hoenen T, Honko AN, Ignatyev GM, Jahrling PB, Johnson JC, Johnson KM, Kindrachuk J, Klenk HD, Kobinger G, Kochel TJ, Lackemeyer MG, Lackner DF, Leroy EM, Lever MS, Mühlberger E, Netesov SV, Olinger GG, Omilabu SA, Palacios G, Panchal RG, Park DJ, Patterson JL, Paweska JT, Peters CJ, Pettitt J, Pitt L, Radoshitzky SR, Ryabchikova EI, Saphire EO, Sabeti PC, Sealfon R, Shestopalov AM, Smither SJ, Sullivan NJ, Swanepoel R, Takada A, Towner JS, van der Groen G, Volchkov VE, Volchkova VA, Wahl-Jensen V, Warren TK, Warfield KL, Weidmann M, Nichol ST. Viruses 6 3663-3682 (2014)
  56. Host Cell Plasma Membrane Phosphatidylserine Regulates the Assembly and Budding of Ebola Virus. Adu-Gyamfi E, Johnson KA, Fraser ME, Scott JL, Soni SP, Jones KR, Digman MA, Gratton E, Tessier CR, Stahelin RV. J Virol 89 9440-9453 (2015)
  57. Inhibition of Marburg virus budding by nonneutralizing antibodies to the envelope glycoprotein. Kajihara M, Marzi A, Nakayama E, Noda T, Kuroda M, Manzoor R, Matsuno K, Feldmann H, Yoshida R, Kawaoka Y, Takada A. J Virol 86 13467-13474 (2012)
  58. A structurally distinct human mycoplasma protein that generically blocks antigen-antibody union. Grover RK, Zhu X, Nieusma T, Jones T, Boreo I, MacLeod AS, Mark A, Niessen S, Kim HJ, Kong L, Assad-Garcia N, Kwon K, Chesi M, Smider VV, Salomon DR, Jelinek DF, Kyle RA, Pyles RB, Glass JI, Ward AB, Wilson IA, Lerner RA. Science 343 656-661 (2014)
  59. Functional interrogation and mining of natively paired human VH:VL antibody repertoires. Wang B, DeKosky BJ, Timm MR, Lee J, Normandin E, Misasi J, Kong R, McDaniel JR, Delidakis G, Leigh KE, Niezold T, Choi CW, Viox EG, Fahad A, Cagigi A, Ploquin A, Leung K, Yang ES, Kong WP, Voss WN, Schmidt AG, Moody MA, Ambrozak DR, Henry AR, Laboune F, Ledgerwood JE, Graham BS, Connors M, Douek DC, Sullivan NJ, Ellington AD, Mascola JR, Georgiou G. Nat Biotechnol 36 152-155 (2018)
  60. Inhibition of Ebola virus entry by a C-peptide targeted to endosomes. Miller EH, Harrison JS, Radoshitzky SR, Higgins CD, Chi X, Dong L, Kuhn JH, Bavari S, Lai JR, Chandran K. J Biol Chem 286 15854-15861 (2011)
  61. Impact of Ebola mucin-like domain on antiglycoprotein antibody responses induced by Ebola virus-like particles. Martinez O, Tantral L, Mulherkar N, Chandran K, Basler CF. J Infect Dis 204 Suppl 3 S825-32 (2011)
  62. Profile and persistence of the virus-specific neutralizing humoral immune response in human survivors of Sudan ebolavirus (Gulu). Sobarzo A, Groseth A, Dolnik O, Becker S, Lutwama JJ, Perelman E, Yavelsky V, Muhammad M, Kuehne AI, Marks RS, Dye JM, Lobel L. J Infect Dis 208 299-309 (2013)
  63. Requirements for cell rounding and surface protein down-regulation by Ebola virus glycoprotein. Francica JR, Matukonis MK, Bates P. Virology 383 237-247 (2009)
  64. Lectin-dependent enhancement of Ebola virus infection via soluble and transmembrane C-type lectin receptors. Brudner M, Karpel M, Lear C, Chen L, Yantosca LM, Scully C, Sarraju A, Sokolovska A, Zariffard MR, Eisen DP, Mungall BA, Kotton DN, Omari A, Huang IC, Farzan M, Takahashi K, Stuart L, Stahl GL, Ezekowitz AB, Spear GT, Olinger GG, Schmidt EV, Michelow IC. PLoS One 8 e60838 (2013)
  65. The cyanobacterial lectin scytovirin displays potent in vitro and in vivo activity against Zaire Ebola virus. Garrison AR, Giomarelli BG, Lear-Rooney CM, Saucedo CJ, Yellayi S, Krumpe LR, Rose M, Paragas J, Bray M, Olinger GG, McMahon JB, Huggins J, O'Keefe BR. Antiviral Res 112 1-7 (2014)
  66. Amiodarone and metabolite MDEA inhibit Ebola virus infection by interfering with the viral entry process. Salata C, Baritussio A, Munegato D, Calistri A, Ha HR, Bigler L, Fabris F, Parolin C, Palù G, Mirazimi A. Pathog Dis 73 (2015)
  67. Designed protein mimics of the Ebola virus glycoprotein GP2 α-helical bundle: stability and pH effects. Harrison JS, Higgins CD, Chandran K, Lai JR. Protein Sci 20 1587-1596 (2011)
  68. Structure of an antibody in complex with its mucin domain linear epitope that is protective against Ebola virus. Olal D, Kuehne AI, Bale S, Halfmann P, Hashiguchi T, Fusco ML, Lee JE, King LB, Kawaoka Y, Dye JM, Saphire EO. J Virol 86 2809-2816 (2012)
  69. Adjuvant-enhanced CD4 T Cell Responses are Critical to Durable Vaccine Immunity. Martins KAO, Cooper CL, Stronsky SM, Norris SLW, Kwilas SA, Steffens JT, Benko JG, van Tongeren SA, Bavari S. EBioMedicine 3 67-78 (2016)
  70. Crystal structure of the Marburg virus GP2 core domain in its postfusion conformation. Koellhoffer JF, Malashkevich VN, Harrison JS, Toro R, Bhosle RC, Chandran K, Almo SC, Lai JR. Biochemistry 51 7665-7675 (2012)
  71. Molecular Basis for Antibody-Mediated Neutralization of New World Hemorrhagic Fever Mammarenaviruses. Mahmutovic S, Clark L, Levis SC, Briggiler AM, Enria DA, Harrison SC, Abraham J. Cell Host Microbe 18 705-713 (2015)
  72. Niemann-pick C1 is essential for ebolavirus replication and pathogenesis in vivo. Herbert AS, Davidson C, Kuehne AI, Bakken R, Braigen SZ, Gunn KE, Whelan SP, Brummelkamp TR, Twenhafel NA, Chandran K, Walkley SU, Dye JM. mBio 6 e00565-15 (2015)
  73. Biochemical Basis for Increased Activity of Ebola Glycoprotein in the 2013-16 Epidemic. Wang MK, Lim SY, Lee SM, Cunningham JM. Cell Host Microbe 21 367-375 (2017)
  74. Target Identification and Mode of Action of Four Chemically Divergent Drugs against Ebolavirus Infection. Ren J, Zhao Y, Fry EE, Stuart DI. J Med Chem 61 724-733 (2018)
  75. Antibody evasion by a gammaherpesvirus O-glycan shield. Machiels B, Lété C, Guillaume A, Mast J, Stevenson PG, Vanderplasschen A, Gillet L. PLoS Pathog 7 e1002387 (2011)
  76. Ebolavirus delta-peptide immunoadhesins inhibit marburgvirus and ebolavirus cell entry. Radoshitzky SR, Warfield KL, Chi X, Dong L, Kota K, Bradfute SB, Gearhart JD, Retterer C, Kranzusch PJ, Misasi JN, Hogenbirk MA, Wahl-Jensen V, Volchkov VE, Cunningham JM, Jahrling PB, Aman MJ, Bavari S, Farzan M, Kuhn JH. J Virol 85 8502-8513 (2011)
  77. Vaccination With a Highly Attenuated Recombinant Vesicular Stomatitis Virus Vector Protects Against Challenge With a Lethal Dose of Ebola Virus. Matassov D, Marzi A, Latham T, Xu R, Ota-Setlik A, Feldmann F, Geisbert JB, Mire CE, Hamm S, Nowak B, Egan MA, Geisbert TW, Eldridge JH, Feldmann H, Clarke DK. J Infect Dis 212 Suppl 2 S443-51 (2015)
  78. Cell entry by a novel European filovirus requires host endosomal cysteine proteases and Niemann-Pick C1. Ng M, Ndungo E, Jangra RK, Cai Y, Postnikova E, Radoshitzky SR, Dye JM, Ramírez de Arellano E, Negredo A, Palacios G, Kuhn JH, Chandran K. Virology 468-470 637-646 (2014)
  79. Facile Discovery of a Diverse Panel of Anti-Ebola Virus Antibodies by Immune Repertoire Mining. Wang B, Kluwe CA, Lungu OI, DeKosky BJ, Kerr SA, Johnson EL, Tanno H, Lee, Jung J, Rezigh AB, Carroll SM, Reyes AN, Bentz JR, Villanueva I, Altman AL, Davey RA, Ellington AD, Georgiou G. Sci Rep 5 13926 (2015)
  80. Peptides modulating conformational changes in secreted chaperones: from in silico design to preclinical proof of concept. Kliger Y, Levy O, Oren A, Ashkenazy H, Tiran Z, Novik A, Rosenberg A, Amir A, Wool A, Toporik A, Schreiber E, Eshel D, Levine Z, Cohen Y, Nold-Petry C, Dinarello CA, Borukhov I. Proc Natl Acad Sci U S A 106 13797-13801 (2009)
  81. The Ebola virus matrix protein VP40 selectively induces vesiculation from phosphatidylserine-enriched membranes. Soni SP, Stahelin RV. J Biol Chem 289 33590-33597 (2014)
  82. An efficient platform for screening expression and crystallization of glycoproteins produced in human cells. Lee JE, Fusco ML, Saphire EO. Nat Protoc 4 592-604 (2009)
  83. Codon-optimized filovirus DNA vaccines delivered by intramuscular electroporation protect cynomolgus macaques from lethal Ebola and Marburg virus challenges. Grant-Klein RJ, Altamura LA, Badger CV, Bounds CE, Van Deusen NM, Kwilas SA, Vu HA, Warfield KL, Hooper JW, Hannaman D, Dupuy LC, Schmaljohn CS. Hum Vaccin Immunother 11 1991-2004 (2015)
  84. Marburg virus glycoprotein GP2: pH-dependent stability of the ectodomain α-helical bundle. Harrison JS, Koellhoffer JF, Chandran K, Lai JR. Biochemistry 51 2515-2525 (2012)
  85. Antibody-Dependent Enhancement of Ebola Virus Infection by Human Antibodies Isolated from Survivors. Kuzmina NA, Younan P, Gilchuk P, Santos RI, Flyak AI, Ilinykh PA, Huang K, Lubaki NM, Ramanathan P, Crowe JE, Bukreyev A. Cell Rep 24 1802-1815.e5 (2018)
  86. Ligand-centered assessment of SARS-CoV-2 drug target models in the Protein Data Bank. Wlodawer A, Dauter Z, Shabalin IG, Gilski M, Brzezinski D, Kowiel M, Minor W, Rupp B, Jaskolski M. FEBS J 287 3703-3718 (2020)
  87. Multiple circulating infections can mimic the early stages of viral hemorrhagic fevers and possible human exposure to filoviruses in Sierra Leone prior to the 2014 outbreak. Boisen ML, Schieffelin JS, Goba A, Oottamasathien D, Jones AB, Shaffer JG, Hastie KM, Hartnett JN, Momoh M, Fullah M, Gabiki M, Safa S, Zandonatti M, Fusco M, Bornholdt Z, Abelson D, Gire SK, Andersen KG, Tariyal R, Stremlau M, Cross RW, Geisbert JB, Pitts KR, Geisbert TW, Kulakoski P, Wilson RB, Henderson L, Sabeti PC, Grant DS, Garry RF, Saphire EO, Branco LM, Khan SH, Viral Hemorrhagic Fever Consortium. Viral Immunol 28 19-31 (2015)
  88. Protective mAbs and Cross-Reactive mAbs Raised by Immunization with Engineered Marburg Virus GPs. Fusco ML, Hashiguchi T, Cassan R, Biggins JE, Murin CD, Warfield KL, Li S, Holtsberg FW, Shulenin S, Vu H, Olinger GG, Kim DH, Whaley KJ, Zeitlin L, Ward AB, Nykiforuk C, Aman MJ, Berry JD, Saphire EO. PLoS Pathog 11 e1005016 (2015)
  89. Characterization of Lassa virus glycoprotein oligomerization and influence of cholesterol on virus replication. Schlie K, Maisa A, Lennartz F, Ströher U, Garten W, Strecker T. J Virol 84 983-992 (2010)
  90. Ebolavirus entry requires a compact hydrophobic fist at the tip of the fusion loop. Gregory SM, Larsson P, Nelson EA, Kasson PM, White JM, Tamm LK. J Virol 88 6636-6649 (2014)
  91. Features of a spatially constrained cystine loop in the p10 FAST protein ectodomain define a new class of viral fusion peptides. Barry C, Key T, Haddad R, Duncan R. J Biol Chem 285 16424-16433 (2010)
  92. Multifunctional Pan-ebolavirus Antibody Recognizes a Site of Broad Vulnerability on the Ebolavirus Glycoprotein. Gilchuk P, Kuzmina N, Ilinykh PA, Huang K, Gunn BM, Bryan A, Davidson E, Doranz BJ, Turner HL, Fusco ML, Bramble MS, Hoff NA, Binshtein E, Kose N, Flyak AI, Flinko R, Orlandi C, Carnahan R, Parrish EH, Sevy AM, Bombardi RG, Singh PK, Mukadi P, Muyembe-Tamfum JJ, Ohi MD, Saphire EO, Lewis GK, Alter G, Ward AB, Rimoin AW, Bukreyev A, Crowe JE. Immunity 49 363-374.e10 (2018)
  93. TIM-1 acts a dual-attachment receptor for Ebolavirus by interacting directly with viral GP and the PS on the viral envelope. Yuan S, Cao L, Ling H, Dang M, Sun Y, Zhang X, Chen Y, Zhang L, Su D, Wang X, Rao Z. Protein Cell 6 814-824 (2015)
  94. Flavonoids as Multi-target Inhibitors for Proteins Associated with Ebola Virus: In Silico Discovery Using Virtual Screening and Molecular Docking Studies. Raj U, Varadwaj PK. Interdiscip Sci 8 132-141 (2016)
  95. Induction of Cell-Cell Fusion by Ebola Virus Glycoprotein: Low pH Is Not a Trigger. Markosyan RM, Miao C, Zheng YM, Melikyan GB, Liu SL, Cohen FS. PLoS Pathog 12 e1005373 (2016)
  96. Selective inhibition of Ebola entry with selective estrogen receptor modulators by disrupting the endolysosomal calcium. Fan H, Du X, Zhang J, Zheng H, Lu X, Wu Q, Li H, Wang H, Shi Y, Gao G, Zhou Z, Tan DX, Li X. Sci Rep 7 41226 (2017)
  97. Chimeric Filoviruses for Identification and Characterization of Monoclonal Antibodies. Ilinykh PA, Shen X, Flyak AI, Kuzmina N, Ksiazek TG, Crowe JE, Bukreyev A. J Virol 90 3890-3901 (2016)
  98. Ebola virus entry into host cells: identifying therapeutic strategies. Rhein BA, Maury WJ. Curr Clin Microbiol Rep 2 115-124 (2015)
  99. A mutation in the Ebola virus envelope glycoprotein restricts viral entry in a host species- and cell-type-specific manner. Martinez O, Ndungo E, Tantral L, Miller EH, Leung LW, Chandran K, Basler CF. J Virol 87 3324-3334 (2013)
  100. Synthetic antibodies with a human framework that protect mice from lethal Sudan ebolavirus challenge. Chen G, Koellhoffer JF, Zak SE, Frei JC, Liu N, Long H, Ye W, Nagar K, Pan G, Chandran K, Dye JM, Sidhu SS, Lai JR. ACS Chem Biol 9 2263-2273 (2014)
  101. Calcium Ions Directly Interact with the Ebola Virus Fusion Peptide To Promote Structure-Function Changes That Enhance Infection. Nathan L, Lai AL, Millet JK, Straus MR, Freed JH, Whittaker GR, Daniel S. ACS Infect Dis 6 250-260 (2020)
  102. Studies of the "chain reversal regions" of the avian sarcoma/leukosis virus (ASLV) and ebolavirus fusion proteins: analogous residues are important, and a His residue unique to EnvA affects the pH dependence of ASLV entry. Delos SE, La B, Gilmartin A, White JM. J Virol 84 5687-5694 (2010)
  103. The Marburgvirus-Neutralizing Human Monoclonal Antibody MR191 Targets a Conserved Site to Block Virus Receptor Binding. King LB, Fusco ML, Flyak AI, Ilinykh PA, Huang K, Gunn B, Kirchdoerfer RN, Hastie KM, Sangha AK, Meiler J, Alter G, Bukreyev A, Crowe JE, Saphire EO. Cell Host Microbe 23 101-109.e4 (2018)
  104. Assembly of the Marburg virus envelope. Mittler E, Kolesnikova L, Herwig A, Dolnik O, Becker S. Cell Microbiol 15 270-284 (2013)
  105. In silico-based vaccine design against Ebola virus glycoprotein. Dash R, Das R, Junaid M, Akash MF, Islam A, Hosen SZ. Adv Appl Bioinform Chem 10 11-28 (2017)
  106. Profiling the native specific human humoral immune response to Sudan Ebola virus strain Gulu by chemiluminescence enzyme-linked immunosorbent assay. Sobarzo A, Perelman E, Groseth A, Dolnik O, Becker S, Lutwama JJ, Dye JM, Yavelsky V, Lobel L, Marks RS. Clin Vaccine Immunol 19 1844-1852 (2012)
  107. Structural Basis of Pan-Ebolavirus Neutralization by a Human Antibody against a Conserved, yet Cryptic Epitope. West BR, Moyer CL, King LB, Fusco ML, Milligan JC, Hui S, Saphire EO. mBio 9 (2018)
  108. Vaccine-elicited receptor-binding site antibodies neutralize two New World hemorrhagic fever arenaviruses. Clark LE, Mahmutovic S, Raymond DD, Dilanyan T, Koma T, Manning JT, Shankar S, Levis SC, Briggiler AM, Enria DA, Wucherpfennig KW, Paessler S, Abraham J. Nat Commun 9 1884 (2018)
  109. Impact of spatial dispersion, evolution, and selection on Ebola Zaire Virus epidemic waves. Azarian T, Lo Presti A, Giovanetti M, Cella E, Rife B, Lai A, Zehender G, Ciccozzi M, Salemi M. Sci Rep 5 10170 (2015)
  110. Residues within the C-terminal arm of the herpes simplex virus 1 glycoprotein B ectodomain contribute to its refolding during the fusion step of virus entry. Connolly SA, Longnecker R. J Virol 86 6386-6393 (2012)
  111. Vaccinating captive chimpanzees to save wild chimpanzees. Warfield KL, Goetzmann JE, Biggins JE, Kasda MB, Unfer RC, Vu H, Aman MJ, Olinger GG, Walsh PD. Proc Natl Acad Sci U S A 111 8873-8876 (2014)
  112. Analytical Validation of the ReEBOV Antigen Rapid Test for Point-of-Care Diagnosis of Ebola Virus Infection. Cross RW, Boisen ML, Millett MM, Nelson DS, Oottamasathien D, Hartnett JN, Jones AB, Goba A, Momoh M, Fullah M, Bornholdt ZA, Fusco ML, Abelson DM, Oda S, Brown BL, Pham H, Rowland MM, Agans KN, Geisbert JB, Heinrich ML, Kulakosky PC, Shaffer JG, Schieffelin JS, Kargbo B, Gbetuwa M, Gevao SM, Wilson RB, Saphire EO, Pitts KR, Khan SH, Grant DS, Geisbert TW, Branco LM, Garry RF. J Infect Dis 214 S210-S217 (2016)
  113. Conformational changes in the Ebola virus membrane fusion machine induced by pH, Ca2+, and receptor binding. Das DK, Bulow U, Diehl WE, Durham ND, Senjobe F, Chandran K, Luban J, Munro JB. PLoS Biol 18 e3000626 (2020)
  114. Conserved B and T cell epitopes prediction of ebola virus glycoprotein for vaccine development: An immuno-informatics approach. Ahmad B, Ashfaq UA, Rahman MU, Masoud MS, Yousaf MZ. Microb Pathog 132 243-253 (2019)
  115. Development of an antibody capture ELISA using inactivated Ebola Zaire Makona virus. Krähling V, Becker D, Rohde C, Eickmann M, Eroğlu Y, Herwig A, Kerber R, Kowalski K, Vergara-Alert J, Becker S, European Mobile Laboratory consortium. Med Microbiol Immunol 205 173-183 (2016)
  116. Mechanistic understanding of N-glycosylation in Ebola virus glycoprotein maturation and function. Wang B, Wang Y, Frabutt DA, Zhang X, Yao X, Hu D, Zhang Z, Liu C, Zheng S, Xiang SH, Zheng YH. J Biol Chem 292 5860-5870 (2017)
  117. Triterpenoids manipulate a broad range of virus-host fusion via wrapping the HR2 domain prevalent in viral envelopes. Si L, Meng K, Tian Z, Sun J, Li H, Zhang Z, Soloveva V, Li H, Fu G, Xia Q, Xiao S, Zhang L, Zhou D. Sci Adv 4 eaau8408 (2018)
  118. A loop region in the N-terminal domain of Ebola virus VP40 is important in viral assembly, budding, and egress. Adu-Gyamfi E, Soni SP, Jee CS, Digman MA, Gratton E, Stahelin RV. Viruses 6 3837-3854 (2014)
  119. Characterization of a Novel Neutralizing Monoclonal Antibody Against Ebola Virus GP. Reynard O, Volchkov VE. J Infect Dis 212 Suppl 2 S372-8 (2015)
  120. Cross-protection conferred by filovirus virus-like particles containing trimeric hybrid glycoprotein. Martins K, Carra JH, Cooper CL, Kwilas SA, Robinson CG, Shurtleff AC, Schokman RD, Kuehl KA, Wells JB, Steffens JT, van Tongeren SA, Hooper JW, Bavari S. Viral Immunol 28 62-70 (2015)
  121. Development of Prototype Filovirus Recombinant Antigen Immunoassays. Boisen ML, Oottamasathien D, Jones AB, Millett MM, Nelson DS, Bornholdt ZA, Fusco ML, Abelson DM, Oda S, Hartnett JN, Rowland MM, Heinrich ML, Akdag M, Goba A, Momoh M, Fullah M, Baimba F, Gbakie M, Safa S, Fonnie R, Kanneh L, Cross RW, Geisbert JB, Geisbert TW, Kulakosky PC, Grant DS, Shaffer JG, Schieffelin JS, Wilson RB, Saphire EO, Branco LM, Garry RF, Khan SH, Pitts KR, Viral Hemorrhagic Fever Consortium. J Infect Dis 212 Suppl 2 S359-67 (2015)
  122. Differential requirements for FcγR engagement by protective antibodies against Ebola virus. Bournazos S, DiLillo DJ, Goff AJ, Glass PJ, Ravetch JV. Proc Natl Acad Sci U S A 116 20054-20062 (2019)
  123. Ebolavirus Glycoprotein Fc Fusion Protein Protects Guinea Pigs against Lethal Challenge. Konduru K, Shurtleff AC, Bradfute SB, Nakamura S, Bavari S, Kaplan G. PLoS One 11 e0162446 (2016)
  124. Functional mutations in spike glycoprotein of Zaire ebolavirus associated with an increase in infection efficiency. Ueda MT, Kurosaki Y, Izumi T, Nakano Y, Oloniniyi OK, Yasuda J, Koyanagi Y, Sato K, Nakagawa S. Genes Cells 22 148-159 (2017)
  125. The crystal structure of the streptococcal collagen-like protein 2 globular domain from invasive M3-type group A Streptococcus shows significant similarity to immunomodulatory HIV protein gp41. Squeglia F, Bachert B, De Simone A, Lukomski S, Berisio R. J Biol Chem 289 5122-5133 (2014)
  126. Asymmetric and non-stoichiometric glycoprotein recognition by two distinct antibodies results in broad protection against ebolaviruses. Milligan JC, Davis CW, Yu X, Ilinykh PA, Huang K, Halfmann PJ, Cross RW, Borisevich V, Agans KN, Geisbert JB, Chennareddy C, Goff AJ, Piper AE, Hui S, Shaffer KCL, Buck T, Heinrich ML, Branco LM, Crozier I, Holbrook MR, Kuhn JH, Kawaoka Y, Glass PJ, Bukreyev A, Geisbert TW, Worwa G, Ahmed R, Saphire EO. Cell 185 995-1007.e18 (2022)
  127. Non-neutralizing Antibodies from a Marburg Infection Survivor Mediate Protection by Fc-Effector Functions and by Enhancing Efficacy of Other Antibodies. Ilinykh PA, Huang K, Santos RI, Gilchuk P, Gunn BM, Karim MM, Liang J, Fouch ME, Davidson E, Parekh DV, Kimble JB, Pietzsch CA, Meyer M, Kuzmina NA, Zeitlin L, Saphire EO, Alter G, Crowe JE, Bukreyev A. Cell Host Microbe 27 976-991.e11 (2020)
  128. Relaxed selection and the evolution of RNA virus mucin-like pathogenicity factors. Wertheim JO, Worobey M. J Virol 83 4690-4694 (2009)
  129. Structural Basis of Pan-Ebolavirus Neutralization by an Antibody Targeting the Glycoprotein Fusion Loop. Murin CD, Bruhn JF, Bornholdt ZA, Copps J, Stanfield R, Ward AB. Cell Rep 24 2723-2732.e4 (2018)
  130. A novel mechanism of immune evasion mediated by Ebola virus soluble glycoprotein. Basler CF. Expert Rev Anti Infect Ther 11 475-478 (2013)
  131. Characterization of Immune Responses Induced by Ebola Virus Glycoprotein (GP) and Truncated GP Isoform DNA Vaccines and Protection Against Lethal Ebola Virus Challenge in Mice. Li W, Ye L, Carrion R, Mohan GS, Nunneley J, Staples H, Ticer A, Patterson JL, Compans RW, Yang C. J Infect Dis 212 Suppl 2 S398-403 (2015)
  132. Ebola virus requires a host scramblase for externalization of phosphatidylserine on the surface of viral particles. Nanbo A, Maruyama J, Imai M, Ujie M, Fujioka Y, Nishide S, Takada A, Ohba Y, Kawaoka Y. PLoS Pathog 14 e1006848 (2018)
  133. Involvement of viral envelope GP2 in Ebola virus entry into cells expressing the macrophage galactose-type C-type lectin. Usami K, Matsuno K, Igarashi M, Denda-Nagai K, Takada A, Irimura T. Biochem Biophys Res Commun 407 74-78 (2011)
  134. Novel mutations in Marburg virus glycoprotein associated with viral evasion from antibody mediated immune pressure. Kajihara M, Nakayama E, Marzi A, Igarashi M, Feldmann H, Takada A. J Gen Virol 94 876-883 (2013)
  135. Repurposing Quinacrine against Ebola Virus Infection In Vivo. Lane TR, Comer JE, Freiberg AN, Madrid PB, Ekins S. Antimicrob Agents Chemother 63 (2019)
  136. The six-helix bundle of human immunodeficiency virus Env controls pore formation and enlargement and is initiated at residues proximal to the hairpin turn. Markosyan RM, Leung MY, Cohen FS. J Virol 83 10048-10057 (2009)
  137. Biophysical characterization and conformational stability of Ebola and Marburg virus-like particles. Hu L, Trefethen JM, Zeng Y, Yee L, Ohtake S, Lechuga-Ballesteros D, Warfield KL, Aman MJ, Shulenin S, Unfer R, Enterlein SG, Truong-Le V, Volkin DB, Joshi SB, Middaugh CR. J Pharm Sci 100 5156-5173 (2011)
  138. Charge-surrounded pockets and electrostatic interactions with small ions modulate the activity of retroviral fusion proteins. Lamb D, Schüttelkopf AW, van Aalten DM, Brighty DW. PLoS Pathog 7 e1001268 (2011)
  139. Cryo-electron Microscopy Structure of the Native Prototype Foamy Virus Glycoprotein and Virus Architecture. Effantin G, Estrozi LF, Aschman N, Renesto P, Stanke N, Lindemann D, Schoehn G, Weissenhorn W. PLoS Pathog 12 e1005721 (2016)
  140. Crystal structures of beta- and gammaretrovirus fusion proteins reveal a role for electrostatic stapling in viral entry. Aydin H, Cook JD, Lee JE. J Virol 88 143-153 (2014)
  141. Design and characterization of endosomal-pH-responsive coiled coils for constructing an artificial membrane fusion system. Kashiwada A, Tsuboi M, Takamura N, Brandenburg E, Matsuda K, Koksch B. Chemistry 17 6179-6186 (2011)
  142. Enhancement of Ebola Virus Infection via Ficolin-1 Interaction with the Mucin Domain of GP Glycoprotein. Favier AL, Gout E, Reynard O, Ferraris O, Kleman JP, Volchkov V, Peyrefitte C, Thielens NM. J Virol 90 5256-5269 (2016)
  143. Enhancement of Ebola virus infection by seminal amyloid fibrils. Bart SM, Cohen C, Dye JM, Shorter J, Bates P. Proc Natl Acad Sci U S A 115 7410-7415 (2018)
  144. Exploiting glycan topography for computational design of Env glycoprotein antigenicity. Yu WH, Zhao P, Draghi M, Arevalo C, Karsten CB, Suscovich TJ, Gunn B, Streeck H, Brass AL, Tiemeyer M, Seaman M, Mascola JR, Wells L, Lauffenburger DA, Alter G. PLoS Comput Biol 14 e1006093 (2018)
  145. Identifying the pattern of molecular evolution for Zaire ebolavirus in the 2014 outbreak in West Africa. Liu SQ, Deng CL, Yuan ZM, Rayner S, Zhang B. Infect Genet Evol 32 51-59 (2015)
  146. Potential neutralizing antibodies discovered for novel corona virus using machine learning. Magar R, Yadav P, Barati Farimani A. Sci Rep 11 5261 (2021)
  147. Requirements within the Ebola Viral Glycoprotein for Tetherin Antagonism. Vande Burgt NH, Kaletsky RL, Bates P. Viruses 7 5587-5602 (2015)
  148. The Tetherin Antagonism of the Ebola Virus Glycoprotein Requires an Intact Receptor-Binding Domain and Can Be Blocked by GP1-Specific Antibodies. Brinkmann C, Nehlmeier I, Walendy-Gnirß K, Nehls J, González Hernández M, Hoffmann M, Qiu X, Takada A, Schindler M, Pöhlmann S. J Virol 90 11075-11086 (2016)
  149. sGP serves as a structural protein in Ebola virus infection. Iwasa A, Shimojima M, Kawaoka Y. J Infect Dis 204 Suppl 3 S897-903 (2011)
  150. Characterization of the receptor-binding domain of Ebola glycoprotein in viral entry. Wang J, Manicassamy B, Caffrey M, Rong L. Virol Sin 26 156-170 (2011)
  151. Conserved peptide vaccine candidates containing multiple Ebola nucleoprotein epitopes display interactions with diverse HLA molecules. Jain S, Baranwal M. Med Microbiol Immunol 208 227-238 (2019)
  152. Development of a Cost-effective Ovine Polyclonal Antibody-Based Product, EBOTAb, to Treat Ebola Virus Infection. Dowall SD, Callan J, Zeltina A, Al-Abdulla I, Strecker T, Fehling SK, Krähling V, Bosworth A, Rayner E, Taylor I, Charlton S, Landon J, Cameron I, Hewson R, Nasidi A, Bowden TA, Carroll MW. J Infect Dis 213 1124-1133 (2016)
  153. Induction of ebolavirus cross-species immunity using retrovirus-like particles bearing the Ebola virus glycoprotein lacking the mucin-like domain. Ou W, Delisle J, Jacques J, Shih J, Price G, Kuhn JH, Wang V, Verthelyi D, Kaplan G, Wilson CA. Virol J 9 32 (2012)
  154. Structural basis of broad ebolavirus neutralization by a human survivor antibody. West BR, Wec AZ, Moyer CL, Fusco ML, Ilinykh PA, Huang K, Wirchnianski AS, James RM, Herbert AS, Hui S, Goodwin E, Howell KA, Kailasan S, Aman MJ, Walker LM, Dye JM, Bukreyev A, Chandran K, Saphire EO. Nat Struct Mol Biol 26 204-212 (2019)
  155. The cytoplasmic domain of Marburg virus GP modulates early steps of viral infection. Mittler E, Kolesnikova L, Hartlieb B, Davey R, Becker S. J Virol 85 8188-8196 (2011)
  156. Computational approaches to therapeutic peptide discovery. Kliger Y. Biopolymers 94 701-710 (2010)
  157. Differential potential for envelope glycoprotein-mediated steric shielding of host cell surface proteins among filoviruses. Noyori O, Matsuno K, Kajihara M, Nakayama E, Igarashi M, Kuroda M, Isoda N, Yoshida R, Takada A. Virology (Lond) 446 152-161 (2013)
  158. Discovery of a junctional epitope antibody that stabilizes IL-6 and gp80 protein:protein interaction and modulates its downstream signaling. Adams R, Burnley RJ, Valenzano CR, Qureshi O, Doyle C, Lumb S, Del Carmen Lopez M, Griffin R, McMillan D, Taylor RD, Meier C, Mori P, Griffin LM, Wernery U, Kinne J, Rapecki S, Baker TS, Lawson AD, Wright M, Ettorre A. Sci Rep 7 37716 (2017)
  159. Early Human B Cell Response to Ebola Virus in Four U.S. Survivors of Infection. Williamson LE, Flyak AI, Kose N, Bombardi R, Branchizio A, Reddy S, Davidson E, Doranz BJ, Fusco ML, Saphire EO, Halfmann PJ, Kawaoka Y, Piper AE, Glass PJ, Crowe JE. J Virol 93 (2019)
  160. Ebola virus envelope glycoprotein derived peptide in human Furin-bound state: computational studies. Omotuyi IO. J Biomol Struct Dyn 33 461-470 (2015)
  161. Selection, characterization, and thermal stabilization of llama single domain antibodies towards Ebola virus glycoprotein. Liu JL, Shriver-Lake LC, Anderson GP, Zabetakis D, Goldman ER. Microb Cell Fact 16 223 (2017)
  162. Specific neutralizing response in plasma from convalescent patients of Ebola Virus Disease against the West Africa Makona variant of Ebola virus. Luczkowiak J, Arribas JR, Gómez S, Jiménez-Yuste V, de la Calle F, Viejo A, Delgado R. Virus Res 213 224-229 (2016)
  163. Vaccine nanoparticles displaying recombinant Ebola virus glycoprotein for induction of potent antibody and polyfunctional T cell responses. Bazzill JD, Stronsky SM, Kalinyak LC, Ochyl LJ, Steffens JT, van Tongeren SA, Cooper CL, Moon JJ. Nanomedicine 18 414-425 (2019)
  164. Application of virus-like particles (VLP) to NMR characterization of viral membrane protein interactions. Antanasijevic A, Kingsley C, Basu A, Bowlin TL, Rong L, Caffrey M. J Biomol NMR 64 255-265 (2016)
  165. Comparative Analysis of Host Cell Entry of Ebola Virus From Sierra Leone, 2014, and Zaire, 1976. Hofmann-Winkler H, Gnirß K, Wrensch F, Pöhlmann S. J Infect Dis 212 Suppl 2 S172-80 (2015)
  166. Development and characterization of rabbit and mouse antibodies against ebolavirus envelope glycoproteins. Ou W, Delisle J, Konduru K, Bradfute S, Radoshitzky SR, Retterer C, Kota K, Bavari S, Kuhn JH, Jahrling PB, Kaplan G, Wilson CA. J Virol Methods 174 99-109 (2011)
  167. Mucin-Like Domain of Ebola Virus Glycoprotein Enhances Selective Oncolytic Actions against Brain Tumors. Zhang X, Zhang T, Davis JN, Marzi A, Marchese AM, Robek MD, van den Pol AN. J Virol 94 e01967-19 (2020)
  168. Virus-Like Particle Vaccination Protects Nonhuman Primates from Lethal Aerosol Exposure with Marburgvirus (VLP Vaccination Protects Macaques against Aerosol Challenges). Dye JM, Warfield KL, Wells JB, Unfer RC, Shulenin S, Vu H, Nichols DK, Aman MJ, Bavari S. Viruses 8 94 (2016)
  169. A thermostable, chromatographically purified Ebola nano-VLP vaccine. Carra JH, Martins KA, Schokman RD, Robinson CG, Steffens JT, Bavari S. J Transl Med 13 228 (2015)
  170. Asymmetric antiviral effects of ebolavirus antibodies targeting glycoprotein stem and glycan cap. Ilinykh PA, Santos RI, Gunn BM, Kuzmina NA, Shen X, Huang K, Gilchuk P, Flyak AI, Younan P, Alter G, Crowe JE, Bukreyev A. PLoS Pathog 14 e1007204 (2018)
  171. Chemically Modified Human Serum Albumin Potently Blocks Entry of Ebola Pseudoviruses and Viruslike Particles. Li H, Yu F, Xia S, Yu Y, Wang Q, Lv M, Wang Y, Jiang S, Lu L. Antimicrob Agents Chemother 61 (2017)
  172. Phenylalanines at positions 88 and 159 of Ebolavirus envelope glycoprotein differentially impact envelope function. Ou W, King H, Delisle J, Shi D, Wilson CA. Virology 396 135-142 (2010)
  173. Possible FDA-approved drugs to treat Ebola virus infection. Yuan S. Infect Dis Poverty 4 23 (2015)
  174. Role of Antibodies in Protection Against Ebola Virus in Nonhuman Primates Immunized With Three Vaccine Platforms. Warfield KL, Howell KA, Vu H, Geisbert J, Wong G, Shulenin S, Sproule S, Holtsberg FW, Leung DW, Amarasinghe GK, Swenson DL, Bavari S, Kobinger GP, Geisbert TW, Aman MJ. J Infect Dis 218 S553-S564 (2018)
  175. Structural Characterization of Pan-Ebolavirus Antibody 6D6 Targeting the Fusion Peptide of the Surface Glycoprotein. Milligan JC, Parekh DV, Fuller KM, Igarashi M, Takada A, Saphire EO. J Infect Dis 219 415-419 (2019)
  176. Structural characterization of a fusion glycoprotein from a retrovirus that undergoes a hybrid 2-step entry mechanism. Aydin H, Smrke BM, Lee JE. FASEB J 27 5059-5071 (2013)
  177. A heterologous prime-boost Ebola virus vaccine regimen induces durable neutralizing antibody response and prevents Ebola virus-like particle entry in mice. Chen T, Li D, Song Y, Yang X, Liu Q, Jin X, Zhou D, Huang Z. Antiviral Res 145 54-59 (2017)
  178. B and T Cell Epitope-Based Peptides Predicted from Evolutionarily Conserved and Whole Protein Sequences of Ebola Virus as Vaccine Targets. Yasmin T, Nabi AH. Scand J Immunol 83 321-337 (2016)
  179. Cross-reactive neutralizing human survivor monoclonal antibody BDBV223 targets the ebolavirus stalk. King LB, West BR, Moyer CL, Gilchuk P, Flyak A, Ilinykh PA, Bombardi R, Hui S, Huang K, Bukreyev A, Crowe JE, Saphire EO. Nat Commun 10 1788 (2019)
  180. Positive Selection Drives Evolution at the Host-Filovirus Interaction Surface. Pontremoli C, Forni D, Cagliani R, Filippi G, De Gioia L, Pozzoli U, Clerici M, Sironi M. Mol Biol Evol 33 2836-2847 (2016)
  181. Production and Purification of Filovirus Glycoproteins in Insect and Mammalian Cell Lines. Clarke EC, Collar AL, Ye C, Caì Y, Anaya E, Rinaldi D, Martinez B, Yarborough S, Merle C, Theisen M, Wada J, Kuhn JH, Bradfute SB. Sci Rep 7 15091 (2017)
  182. Quantitative serology assays for determination of antibody responses to Ebola virus glycoprotein and matrix protein in nonhuman primates and humans. Vu H, Shulenin S, Grolla A, Audet J, He S, Kobinger G, Unfer RC, Warfield KL, Aman MJ, Holtsberg FW. Antiviral Res 126 55-61 (2016)
  183. Real-Time Analysis of Individual Ebola Virus Glycoproteins Reveals Pre-Fusion, Entry-Relevant Conformational Dynamics. Durham ND, Howard AR, Govindan R, Senjobe F, Fels JM, Diehl WE, Luban J, Chandran K, Munro JB. Viruses 12 (2020)
  184. Simple, automated, high resolution mass spectrometry method to determine the disulfide bond and glycosylation patterns of a complex protein: subgroup A avian sarcoma and leukosis virus envelope glycoprotein. Pike GM, Madden BJ, Melder DC, Charlesworth MC, Federspiel MJ. J Biol Chem 286 17954-17967 (2011)
  185. A Hyperstabilizing Mutation in the Base of the Ebola Virus Glycoprotein Acts at Multiple Steps To Abrogate Viral Entry. Fels JM, Spence JS, Bortz RH, Bornholdt ZA, Chandran K. mBio 10 (2019)
  186. Influence of a heptad repeat stutter on the pH-dependent conformational behavior of the central coiled-coil from influenza hemagglutinin HA2. Higgins CD, Malashkevich VN, Almo SC, Lai JR. Proteins 82 2220-2228 (2014)
  187. Molecular modeling, simulation and docking study of ebola virus glycoprotein. Ahmad N, Farman A, Badshah SL, Ur Rahman A, Ur Rashid H, Khan K. J Mol Graph Model 72 266-271 (2017)
  188. Site-specific fab fragment biotinylation at the conserved nucleotide binding site for enhanced Ebola detection. Mustafaoglu N, Alves NJ, Bilgicer B. Biotechnol Bioeng 112 1327-1334 (2015)
  189. Structural and Functional Studies on the Marburg Virus GP2 Fusion Loop. Liu N, Tao Y, Brenowitz MD, Girvin ME, Lai JR. J Infect Dis 212 Suppl 2 S146-53 (2015)
  190. Successful post-exposure prophylaxis of Ebola infected non-human primates using Ebola glycoprotein-specific equine IgG. Pyankov OV, Setoh YX, Bodnev SA, Edmonds JH, Pyankova OG, Pyankov SA, Pali G, Belford S, Lu L, La M, Lovrecz G, Volchkova VA, Chappell KJ, Watterson D, Marsh G, Young PR, Agafonov AA, Farmer JF, Volchkov VE, Suhrbier A, Khromykh AA. Sci Rep 7 41537 (2017)
  191. Tackling Ebola: new insights into prophylactic and therapeutic intervention strategies. de Wit E, Feldmann H, Munster VJ. Genome Med 3 5 (2011)
  192. Addicted to sugar: roles of glycans in the order Mononegavirales. Ortega V, Stone JA, Contreras EM, Iorio RM, Aguilar HC. Glycobiology 29 2-21 (2019)
  193. Amino acid mutations in Ebola virus glycoprotein of the 2014 epidemic. Giovanetti M, Grifoni A, Lo Presti A, Cella E, Montesano C, Zehender G, Colizzi V, Amicosante M, Ciccozzi M. J Med Virol 87 893-898 (2015)
  194. Antibody Repertoires to the Same Ebola Vaccine Antigen Are Differentially Affected by Vaccine Vectors. Meyer M, Yoshida A, Ramanathan P, Saphire EO, Collins PL, Crowe JE, Samal S, Bukreyev A. Cell Rep 24 1816-1829 (2018)
  195. Assessment of the ability of V920 recombinant vesicular stomatitis-Zaire ebolavirus vaccine to replicate in relevant arthropod cell cultures and vector species. Bergren NA, Miller MR, Monath TP, Kading RC. Hum Vaccin Immunother 14 994-1002 (2018)
  196. Conformational properties of peptides corresponding to the ebolavirus GP2 membrane-proximal external region in the presence of micelle-forming surfactants and lipids. Regula LK, Harris R, Wang F, Higgins CD, Koellhoffer JF, Zhao Y, Chandran K, Gao J, Girvin ME, Lai JR. Biochemistry 52 3393-3404 (2013)
  197. Research Support, Non-U.S. Gov't Do therapeutic antibodies hold the key to an effective treatment for Ebola hemorrhagic fever? Takada A. Immunotherapy 5 441-443 (2013)
  198. Ebola vaccine-induced protection in nonhuman primates correlates with antibody specificity and Fc-mediated effects. Meyer M, Gunn BM, Malherbe DC, Gangavarapu K, Yoshida A, Pietzsch C, Kuzmina NA, Saphire EO, Collins PL, Crowe JE, Zhu JJ, Suchard MA, Brining DL, Mire CE, Cross RW, Geisbert JB, Samal SK, Andersen KG, Alter G, Geisbert TW, Bukreyev A. Sci Transl Med 13 eabg6128 (2021)
  199. Epitope mapping of Ebola virus dominant and subdominant glycoprotein epitopes facilitates construction of an epitope-based DNA vaccine able to focus the antibody response in mice. Mitchell DAJ, Dupuy LC, Sanchez-Lockhart M, Palacios G, Back JW, Shimanovskaya K, Chaudhury S, Ripoll DR, Wallqvist A, Schmaljohn CS. Hum Vaccin Immunother 13 2883-2893 (2017)
  200. Involvement of Surfactant Protein D in Ebola Virus Infection Enhancement via Glycoprotein Interaction. Favier AL, Reynard O, Gout E, van Eijk M, Haagsman HP, Crouch E, Volchkov V, Peyrefitte C, Thielens NM. Viruses 11 (2018)
  201. Membrane insertion of fusion peptides from Ebola and Marburg viruses studied by replica-exchange molecular dynamics simulations. Olson MA, Lee MS, Yeh IC. J Comput Chem 38 1342-1352 (2017)
  202. Minimal In Vivo Efficacy of Iminosugars in a Lethal Ebola Virus Guinea Pig Model. Miller JL, Spiro SG, Dowall SD, Taylor I, Rule A, Alonzi DS, Sayce AC, Wright E, Bentley EM, Thom R, Hall G, Dwek RA, Hewson R, Zitzmann N. PLoS One 11 e0167018 (2016)
  203. Proteomics Computational Analyses Suggest that the Antennavirus Glycoprotein Complex Includes a Class I Viral Fusion Protein (α-Penetrene) with an Internal Zinc-Binding Domain and a Stable Signal Peptide. Garry CE, Garry RF. Viruses 11 (2019)
  204. Single low-dose VSV-EBOV vaccination protects cynomolgus macaques from lethal Ebola challenge. Marzi A, Reynolds P, Mercado-Hernandez R, Callison J, Feldmann F, Rosenke R, Thomas T, Scott DP, Hanley PW, Haddock E, Feldmann H. EBioMedicine 49 223-231 (2019)
  205. Single residues in the surface subunits of oncogenic sheep retrovirus envelopes distinguish receptor-mediated triggering for fusion at low pH and infection. Côté M, Zheng YM, Albritton LM, Liu SL. Virology 421 173-183 (2011)
  206. Vaccine Generation of Protective Ebola Antibodies and Identification of Conserved B-Cell Signatures. Cagigi A, Misasi J, Ploquin A, Stanley DA, Ambrozak D, Tsybovsky Y, Mason RD, Roederer M, Sullivan NJ. J Infect Dis 218 S528-S536 (2018)
  207. A convenient and general expression platform for the production of secreted proteins from human cells. Aydin H, Azimi FC, Cook JD, Lee JE. J Vis Exp (2012)
  208. Antibody Derived Peptides for Detection of Ebola Virus Glycoprotein. Rodríguez-Martínez LM, Marquez-Ipiña AR, López-Pacheco F, Pérez-Chavarría R, González-Vázquez JC, González-González E, Trujillo-de Santiago G, Ponce-Ponce de León CA, Zhang YS, Dokmeci MR, Khademhosseini A, Alvarez MM. PLoS One 10 e0135859 (2015)
  209. Antibody-Mediated Protective Mechanisms Induced by a Trivalent Parainfluenza Virus-Vectored Ebolavirus Vaccine. Kimble JB, Malherbe DC, Meyer M, Gunn BM, Karim MM, Ilinykh PA, Iampietro M, Mohamed KS, Negi S, Gilchuk P, Huang K, Wolf YI, Braun W, Crowe JE, Alter G, Bukreyev A. J Virol 93 (2019)
  210. Cell-cell contact promotes Ebola virus GP-mediated infection. Miao C, Li M, Zheng YM, Cohen FS, Liu SL. Virology 488 202-215 (2016)
  211. Curcumin and Natural Derivatives Inhibit Ebola Viral Proteins: An In silico Approach. Baikerikar S. Pharmacognosy Res 9 S15-S22 (2017)
  212. Design of Fusion Proteins for Efficient and Soluble Production of Immunogenic Ebola Virus Glycoprotein in Escherichia coli. Ji Y, Lu Y, Yan Y, Liu X, Su N, Zhang C, Bi S, Xing XH. Biotechnol J 13 e1700627 (2018)
  213. In silico screening of sugar alcohol compounds to inhibit viral matrix protein VP40 of Ebola virus. Nagarajan N, Yapp EKY, Le NQK, Yeh HY. Mol Biol Rep 46 3315-3324 (2019)
  214. Sequential activation of the three protomers in the Moloney murine leukemia virus Env. Sjöberg M, Löving R, Lindqvist B, Garoff H. Proc Natl Acad Sci U S A 114 2723-2728 (2017)
  215. Single-component multilayered self-assembling nanoparticles presenting rationally designed glycoprotein trimers as Ebola virus vaccines. He L, Chaudhary A, Lin X, Sou C, Alkutkar T, Kumar S, Ngo T, Kosviner E, Ozorowski G, Stanfield RL, Ward AB, Wilson IA, Zhu J. Nat Commun 12 2633 (2021)
  216. The Role of the Charged Residues of the GP2 Helical Regions in Ebola Entry(). Jiang H, Wang J, Manicassamy B, Manicassamy S, Caffrey M, Rong L. Virol Sin 24 121-135 (2009)
  217. A Glycoprotein Mutation That Emerged during the 2013-2016 Ebola Virus Epidemic Alters Proteolysis and Accelerates Membrane Fusion. Fels JM, Bortz RH, Alkutkar T, Mittler E, Jangra RK, Spence JS, Chandran K. mBio 12 e03616-20 (2021)
  218. Analysis of Resistance of Ebola Virus Glycoprotein-Driven Entry Against MDL28170, An Inhibitor of Cysteine Cathepsins. Hoffmann M, Kaufmann SV, Fischer C, Maurer W, Moldenhauer AS, Pöhlmann S. Pathogens 8 (2019)
  219. Anti-Niemann Pick C1 Single-Stranded Oligonucleotides with Locked Nucleic Acids Potently Reduce Ebola Virus Infection In Vitro. Sadewasser A, Dietzel E, Michel S, Klüver M, Helfer M, Thelemann T, Klar R, Eickmann M, Becker S, Jaschinski F. Mol Ther Nucleic Acids 16 686-697 (2019)
  220. Comparative analyses of small molecule and antibody inhibition on glycoprotein-mediated entry of Měnglà virus with other filoviruses. Cooper L, Galvan Achi J, Rong L. J Med Virol 94 3263-3269 (2022)
  221. Design and evaluation of bi- and trispecific antibodies targeting multiple filovirus glycoproteins. Nyakatura EK, Zak SE, Wec AZ, Hofmann D, Shulenin S, Bakken RR, Aman MJ, Chandran K, Dye JM, Lai JR. J Biol Chem 293 6201-6211 (2018)
  222. Designing a novel multi‑epitope vaccine against Ebola virus using reverse vaccinology approach. Alizadeh M, Amini-Khoei H, Tahmasebian S, Ghatrehsamani M, Ghatreh Samani K, Edalatpanah Y, Rostampur S, Salehi M, Ghasemi-Dehnoo M, Azadegan-Dehkordi F, Sanami S, Bagheri N. Sci Rep 12 7757 (2022)
  223. Discovery and Structural Optimization of 4-(Aminomethyl)benzamides as Potent Entry Inhibitors of Ebola and Marburg Virus Infections. Gaisina IN, Peet NP, Wong L, Schafer AM, Cheng H, Anantpadma M, Davey RA, Thatcher GRJ, Rong L. J Med Chem 63 7211-7225 (2020)
  224. Dual monoclonal antibody-based sandwich ELISA for detection of in vitro packaged Ebola virus. Zai J, Yi K, Xie L, Zhu J, Feng X, Li Y. Diagn Pathol 13 96 (2018)
  225. Generation of vero cells expressing ebola virus glycoprotein. Makino A, Kawaoka Y. J Vet Med Sci 71 505-507 (2009)
  226. Human antibody pieces together the puzzle of the trimeric Lassa virus surface antigen. Zeltina A, Bowden TA. Nat Struct Mol Biol 24 559-560 (2017)
  227. Identification of potential inhibitors of protein-protein interaction useful to fight against Ebola and other highly pathogenic viruses. Lasala F, García-Rubia A, Requena C, Galindo I, Cuesta-Geijo MA, García-Dorival I, Bueno P, Labiod N, Luczkowiak J, Martinez A, Campillo NE, Alonso C, Delgado R, Gil C. Antiviral Res 186 105011 (2021)
  228. Mechanistic and Fc requirements for inhibition of Sudan virus entry and in vivo protection by a synthetic antibody. Hofmann D, Zak SE, Nyakatura EK, Mittler E, Bakken RR, Chandran K, Dye JM, Lai JR. Immunol Lett 190 289-295 (2017)
  229. Pan-ebolavirus protective therapy by two multifunctional human antibodies. Gilchuk P, Murin CD, Cross RW, Ilinykh PA, Huang K, Kuzmina N, Borisevich V, Agans KN, Geisbert JB, Zost SJ, Nargi RS, Sutton RE, Suryadevara N, Bombardi RG, Carnahan RH, Bukreyev A, Geisbert TW, Ward AB, Crowe JE. Cell 184 5593-5607.e18 (2021)
  230. Parainfluenza virus entry at the onset of infection. Marcink TC, Porotto M, Moscona A. Adv Virus Res 111 1-29 (2021)
  231. Preservation of Quaternary Structure in Thermostable, Lyophilized Filovirus Glycoprotein Vaccines: A Search for Stability-Indicating Assays. Preston KB, Monticello CR, Wong TAS, To A, Donini O, Lehrer AT, Randolph TW. J Pharm Sci 109 3716-3727 (2020)
  232. Proteomics Computational Analyses Suggest That the Envelope Glycoproteins of Segmented Jingmen Flavi-Like Viruses are Class II Viral Fusion Proteins (b-Penetrenes) with Mucin-Like Domains. Garry CE, Garry RF. Viruses 12 (2020)
  233. Pseudotyping of VSV with Ebola virus glycoprotein is superior to HIV-1 for the assessment of neutralising antibodies. Steeds K, Hall Y, Slack GS, Longet S, Strecker T, Fehling SK, Wright E, Bore JA, Koundouno FR, Konde MK, Hewson R, Hiscox JA, Pollakis G, Carroll MW. Sci Rep 10 14289 (2020)
  234. Recombinant subunit vaccines protect guinea pigs from lethal Ebola virus challenge. Lehrer AT, Wong TS, Lieberman MM, Johns L, Medina L, Feldmann F, Feldmann H, Marzi A. Vaccine 37 6942-6950 (2019)
  235. Role of the Ebola membrane in the protection conferred by the three-mAb cocktail MIL77. Cao P, Bai H, Wang X, Che J. Sci Rep 8 17628 (2018)
  236. Synthetic Carbohydrate Chemistry and Translational Medicine. Shivatare SS, Wong CH. J Org Chem 85 15780-15800 (2020)
  237. The PDB database is a rich source of alpha-helical anti-microbial peptides to combat disease causing pathogens. Chakraborty S, Phu M, de Morais TP, Nascimento R, Goulart LR, Rao BJ, Asgeirsson B, Dandekar AM. F1000Res 3 295 (2014)
  238. The Roles of Histidines and Charged Residues as Potential Triggers of a Conformational Change in the Fusion Loop of Ebola Virus Glycoprotein. Lee J, Gregory SM, Nelson EA, White JM, Tamm LK. PLoS One 11 e0152527 (2016)
  239. The shape of pleomorphic virions determines resistance to cell-entry pressure. Li T, Li Z, Deans EE, Mittler E, Liu M, Chandran K, Ivanovic T. Nat Microbiol 6 617-629 (2021)
  240. A Virion-Based Assay for Glycoprotein Thermostability Reveals Key Determinants of Filovirus Entry and Its Inhibition. Bortz RH, Wong AC, Grodus MG, Recht HS, Pulanco MC, Lasso G, Anthony SJ, Mittler E, Jangra RK, Chandran K. J Virol 94 (2020)
  241. A new strategy for full-length Ebola virus glycoprotein expression in E.coli. Zai J, Yi Y, Xia H, Zhang B, Yuan Z. Virol Sin 31 500-508 (2016)
  242. Conformational and lipid bilayer-perturbing properties of Marburg virus GP2 segments containing the fusion loop and membrane-proximal external region/transmembrane domain. Liu N, Girvin ME, Brenowitz M, Lai JR. Heliyon 5 e03018 (2019)
  243. Development and characterization of influenza M2 ectodomain and/or hemagglutinin stalk-based dendritic cell-targeting vaccines. Olukitibi TA, Ao Z, Azizi H, Mahmoudi M, Coombs K, Kobasa D, Kobinger G, Yao X. Front Microbiol 13 937192 (2022)
  244. Direct Intracellular Visualization of Ebola Virus-Receptor Interaction by In Situ Proximity Ligation. Mittler E, Alkutkar T, Jangra RK, Chandran K. mBio 12 (2021)
  245. Ebola images emerge from the cave. Diamond MS, Fremont DH. Cell Host Microbe 4 87-89 (2008)
  246. Evidence for distinct mechanisms of small molecule inhibitors of filovirus entry. Schafer A, Xiong R, Cooper L, Nowar R, Lee H, Li Y, Ramirez BE, Peet NP, Caffrey M, Thatcher GRJ, Saphire EO, Cheng H, Rong L. PLoS Pathog 17 e1009312 (2021)
  247. Filoviruses Use the HOPS Complex and UVRAG To Traffic to Niemann-Pick C1 Compartments during Viral Entry. Bo Y, Qiu S, Mulloy RP, Côté M. J Virol 94 (2020)
  248. Immunogenicity of a Candidate Ebola Hemorrhagic Fever Vaccine in Mice Based on Controlled In Vitro Expression of Ebolavirus Glycoprotein. Kumar D, Gauthami S, Uma M, Nagalekshmi K, Rao PP, Basu A, Ella KM, Hegde NR. Viral Immunol 31 500-512 (2018)
  249. In silico prediction of Ebola Zaire GP(1,2) immuno-dominant epitopes for the Balb/c mouse. Dutta DK, Rhodes K, Wood SC. BMC Immunol 16 59 (2015)
  250. Mapping the clinical outcomes and genetic evolution of Ebola virus in Sierra Leone. Li T, Yao HW, Liu D, Ren HG, Hu Y, Kargbo D, Teng Y, Deng YQ, Lu HJ, Liu X, Liu K, Fang LQ, Ning NZ, Wong G, Dafae F, Kamara A, Wu A, Jiang TJ, Li Z, Huang J, Sun Y, Qian J, Kargbo B, Jiang JF, Wang H, Cao WC. JCI Insight 2 (2017)
  251. Molecular and functional insights into a novel teleost malectin from big-belly seahorse Hippocampus abdominalis. Sellaththurai S, Shanaka KASN, Liyanage DS, Yang H, Priyathilaka TT, Lee J. Fish Shellfish Immunol 99 483-494 (2020)
  252. Multimerization of Ebola GPΔmucin on protein nanoparticle vaccines has minimal effect on elicitation of neutralizing antibodies. Powell AE, Xu D, Roth GA, Zhang K, Chiu W, Appel EA, Kim PS. Front Immunol 13 942897 (2022)
  253. New hope in the search for Ebola virus treatments. Basler CF. Immunity 41 515-517 (2014)
  254. Overexpression of Ebola virus envelope GP1 protein. Zou Z, Misasi J, Sullivan N, Sun PD. Protein Expr Purif 135 45-53 (2017)
  255. RT-PCR using glycoprotein target is more sensitive for the detection of Ebola virus in clinical samples. Yang M, Ke Y, Zhang W, Liu C, Yang R, Chen Z. Diagn Microbiol Infect Dis 87 235-237 (2017)
  256. Recombinant Antibodies to the Ebola Virus Glycoprotein. Panina AA, Dementieva IG, Aliev TK, Toporova VA, Balabashin DS, Bokov MN, Pozdnyakova LP, Shchemchukova OB, Dolgikh DA, Sveshnikov PG, Kirpichnikov MP. Acta Naturae 9 84-91 (2017)
  257. THE STRENGTHS, WEAKNESSES, OPPORTUNITIES, AND THREATS (SWOTs) ANALYSES OF THE EBOLA VIRUS - PAPER RETRACTED. Babalola MO. Afr J Infect Dis 10 69-88 (2016)
  258. X-ray Structures of the Post-fusion 6-Helix Bundle of the Human Syncytins and their Functional Implications. Ruigrok K, Vaney MC, Buchrieser J, Baquero E, Hellert J, Baron B, England P, Schwartz O, Rey FA, Backovic M. J Mol Biol 431 4922-4940 (2019)
  259. In Silico Analyses, Experimental Verification and Application in DNA Vaccines of Ebolavirus GP-Derived pan-MHC-II-Restricted Epitopes. Zhang J, Sun B, Shen W, Wang Z, Liu Y, Sun Y, Zhang J, Liu R, Wang Y, Bai T, Ma Z, Luo C, Qiao X, Zhang X, Yang S, Sun Y, Jiang D, Yang K. Vaccines (Basel) 11 1620 (2023)
  260. N'-Phenylacetohydrazide Derivatives as Potent Ebola Virus Entry Inhibitors with an Improved Pharmacokinetic Profile. Garcia-Rubia A, Lasala F, Ginex T, Morales-Tenorio M, Olal C, Heung M, Oquist P, Galindo I, Cuesta-Geijo MÁ, Casasnovas JM, Campillo NE, Canales Á, Alonso C, Martínez A, Muñoz-Fontela C, Delgado R, Gil C. J Med Chem 66 5465-5483 (2023)
  261. A Naturally Occurring Polymorphism in the Base of Sudan Virus Glycoprotein Decreases Glycoprotein Stability in a Species-Dependent Manner. Lennemann NJ, Dillard J, Ruggio N, Cooney AL, Schaack GA, Davey RA, Maury W. J Virol 95 e0107321 (2021)
  262. A rabies virus-vectored vaccine expressing two copies of the Marburg virus glycoprotein gene induced neutralizing antibodies against Marburg virus in humanized mice. Bi J, Wang H, Han Q, Pei H, Wang H, Jin H, Jin S, Chi H, Yang S, Zhao Y, Yan F, Ge L, Xia X. Emerg Microbes Infect 12 2149351 (2023)
  263. A single immunization with a modified vaccinia Ankara vectored vaccine producing Sudan virus-like particles protects from lethal infection. Malherbe DC, Domi A, Hauser MJ, Atyeo C, Fischinger S, Hyde MA, Williams JM, Alter G, Guirakhoo F, Bukreyev A. NPJ Vaccines 7 83 (2022)
  264. A versatile platform technology for recombinant vaccines using non-propagative human parainfluenza virus type 2 vector. Ohtsuka J, Fukumura M, Furuyama W, Wang S, Hara K, Maeda M, Tsurudome M, Miyamoto H, Kaito A, Tsuda N, Kataoka Y, Mizoguchi A, Takada A, Nosaka T. Sci Rep 9 12901 (2019)
  265. Activating Natural Killer Cell Receptors, Selectins, and Inhibitory Siglecs Recognize Ebolavirus Glycoprotein. Jarahian M, Marstaller K, Banna N, Ahani R, Etemadzadeh MH, Boller LK, Azadmanesh K, Cid-Arregui A, Khezri A, Berger MR, Momburg F, Watzl C. J Innate Immun 14 135-147 (2022)
  266. Antibody affinity as a driver of signal generation in a paper-based immunoassay for Ebola virus surveillance. Murray LP, Govindan R, Mora AC, Munro JB, Mace CR. Anal Bioanal Chem 413 3695-3706 (2021)
  267. Blocking of ebolavirus spread through intercellular connections by an MPER-specific antibody depends on BST2/tetherin. Santos RI, Ilinykh PA, Pietzsch CA, Ronk AJ, Huang K, Kuzmina NA, Zhou F, Crowe JE, Bukreyev A. Cell Rep 42 113254 (2023)
  268. Cellular factors implicated in filovirus entry. Bhattacharyya S, Hope TJ. Adv Virol 2013 487585 (2013)
  269. Computational epitope mapping of class I fusion proteins using low complexity supervised learning methods. Fischer MFS, Crowe JE, Meiler J. PLoS Comput Biol 18 e1010230 (2022)
  270. Cyanovirin-N Binds Viral Envelope Proteins at the Low-Affinity Carbohydrate Binding Site without Direct Virus Neutralization Ability. Maier I, Schiestl RH, Kontaxis G. Molecules 26 (2021)
  271. Designs and Characterization of Subunit Ebola GP Vaccine Candidates: Implications for Immunogenicity. Agnolon V, Kiseljak D, Wurm MJ, Wurm FM, Foissard C, Gallais F, Wehrle S, Muñoz-Fontela C, Bellanger L, Correia BE, Corradin G, Spertini F. Front Immunol 11 586595 (2020)
  272. Development and Evaluation of an Ebola Virus Glycoprotein Mucin-Like Domain Replacement System as a New Dendritic Cell-Targeting Vaccine Approach against HIV-1. Ao Z, Wang L, Azizi H, Olukitibi TA, Kobinger G, Yao X. J Virol 95 e0236820 (2021)
  273. Development of an imaging system for visualization of Ebola virus glycoprotein throughout the viral lifecycle. Furuyama W, Sakaguchi M, Yamada K, Nanbo A. Front Microbiol 13 1026644 (2022)
  274. Ebola Virus Uses Tunneling Nanotubes as an Alternate Route of Dissemination. Djurkovic MA, Leavitt CG, Arnett E, Kriachun V, Martínez-Sobrido L, Titone R, Sherwood LJ, Hayhurst A, Schlesinger LS, Shtanko O. J Infect Dis 228 S522-S535 (2023)
  275. Ebola virus protein VP40 stimulates IL-12- and IL-18-dependent activation of human natural killer cells. Le H, Spearman P, Waggoner SN, Singh K. JCI Insight 7 e158902 (2022)
  276. Engineered Human Monoclonal scFv to Receptor Binding Domain of Ebolavirus. Densumite J, Phanthong S, Seesuay W, Sookrung N, Chaisri U, Chaicumpa W. Vaccines (Basel) 9 (2021)
  277. Entry of Ebola Virus is an Asynchronous Process. Reynard O, Volchkov VE. J Infect Dis 212 Suppl 2 S199-203 (2015)
  278. Epitope-focused immunogen design based on the ebolavirus glycoprotein HR2-MPER region. Schoeder CT, Gilchuk P, Sangha AK, Ledwitch KV, Malherbe DC, Zhang X, Binshtein E, Williamson LE, Martina CE, Dong J, Armstrong E, Sutton R, Nargi R, Rodriguez J, Kuzmina N, Fiala B, King NP, Bukreyev A, Crowe JE, Meiler J. PLoS Pathog 18 e1010518 (2022)
  279. Identification and Characterization of a Novel Single Domain Antibody Against Ebola Virus. Wang R, Zhang H, Peng C, Shi J, Zhang H, Gong R. Virol Sin 36 1600-1610 (2021)
  280. Identification of Novel Adjuvants for Ebola Virus-Like Particle Vaccine. Feng H, Nakatsu S, Lopes TJDS, Imai M, Yamayoshi S, Yamashita M, Watanabe T, Kawaoka Y. Vaccines (Basel) 8 (2020)
  281. Improved computational epitope profiling using structural models identifies a broader diversity of antibodies that bind to the same epitope. Spoendlin FC, Abanades B, Raybould MIJ, Wong WK, Georges G, Deane CM. Front Mol Biosci 10 1237621 (2023)
  282. Limited Evidence for a Relationship between HIV-1 Glycan Shield Features in Early Infection and the Development of Neutralization Breadth. Li Y, Bai H, Sanders-Buell E, Dussupt V, Townsley S, Donofrio G, Bose M, O'Sullivan AM, Kibuuka H, Maganga L, Nitayaphan S, Kosgei J, Pitisuttithum P, Rerks-Ngarm S, Eller LA, Michael NL, Robb ML, Ake J, Vasan S, Tovanabutra S, Krebs SJ, Rolland M. J Virol 95 e0079721 (2021)
  283. Natural history of Ebola virus disease in rhesus monkeys shows viral variant emergence dynamics and tissue-specific host responses. Normandin E, Triana S, Raju SS, Lan TCT, Lagerborg K, Rudy M, Adams GC, DeRuff KC, Logue J, Liu D, Strebinger D, Rao A, Messer KS, Sacks M, Adams RD, Janosko K, Kotliar D, Shah R, Crozier I, Rinn JL, Melé M, Honko AN, Zhang F, Babadi M, Luban J, Bennett RS, Shalek AK, Barkas N, Lin AE, Hensley LE, Sabeti PC, Siddle KJ. Cell Genom 3 100440 (2023)
  284. Pan-ebolavirus serology study of healthcare workers in the Mbandaka Health Region, Democratic Republic of the Congo. Shaffer KCL, Hui S, Bratcher A, King LB, Mutombe R, Kavira N, Kompany JP, Tambu M, Musene K, Mukadi P, Mbala P, Gadoth A, West BR, Ilunga BK, Kaba D, Muyembe-Tanfum JJ, Hoff NA, Rimoin AW, Saphire EO. PLoS Negl Trop Dis 16 e0010167 (2022)
  285. Proteo-Genomic Analysis Identifies Two Major Sites of Vulnerability on Ebolavirus Glycoprotein for Neutralizing Antibodies in Convalescent Human Plasma. Gilchuk P, Guthals A, Bonissone SR, Shaw JB, Ilinykh PA, Huang K, Bombardi RG, Liang J, Grinyo A, Davidson E, Chen EC, Gunn BM, Alter G, Saphire EO, Doranz BJ, Bukreyev A, Zeitlin L, Castellana N, Crowe JE. Front Immunol 12 706757 (2021)
  286. Pseudotyped Viruses for Marburgvirus and Ebolavirus. Zhang L, Liu S, Wang Y. Adv Exp Med Biol 1407 105-132 (2023)
  287. Purification and structure of luminal domain C of human Niemann-Pick C1 protein. Odongo L, Zadrozny KK, Diehl WE, Luban J, White JM, Ganser-Pornillos BK, Tamm LK, Pornillos O. Acta Crystallogr F Struct Biol Commun 79 45-50 (2023)
  288. Regulation of Ebola GP conformation and membrane binding by the chemical environment of the late endosome. Jain A, Govindan R, Berkman AR, Luban J, Díaz-Salinas MA, Durham ND, Munro JB. PLoS Pathog 19 e1011848 (2023)
  289. Structural Insights into the Interaction of Filovirus Glycoproteins with the Endosomal Receptor Niemann-Pick C1: A Computational Study. Igarashi M, Hirokawa T, Takadate Y, Takada A. Viruses 13 (2021)
  290. Subnanometer structure of an enveloped virus fusion complex on viral surface reveals new entry mechanisms. Marcink TC, Zipursky G, Cheng W, Stearns K, Stenglein S, Golub K, Cohen F, Bovier F, Pfalmer D, Greninger AL, Porotto M, des Georges A, Moscona A. Sci Adv 9 eade2727 (2023)
  291. The Art of Viral Membrane Fusion and Penetration. Winter SL, Chlanda P. Subcell Biochem 106 113-152 (2023)
  292. The Importance of Glycosylation in COVID-19 Infection. Petrović T, Lauc G, Trbojević-Akmačić I. Adv Exp Med Biol 1325 239-264 (2021)
  293. The Mucin-Like Domain of the Ebola Glycoprotein Does Not Impact Virulence or Pathogenicity in Ferrets. Halfmann PJ, Borisevich V, Levine CB, Mire CE, Fenton KA, Geisbert TW, Kawaoka Y, Cross RW. J Infect Dis 228 S587-S593 (2023)
  294. Tracking ebolavirus genomic drift with a resequencing microarray. Tiper I, Kourout M, Fisher C, Konduru K, Purkayastha A, Kaplan G, Duncan R. PLoS One 17 e0263732 (2022)
  295. Unique Mode of Antiviral Action of a Marine Alkaloid against Ebola Virus and SARS-CoV-2. Izumida M, Kotani O, Hayashi H, Smith C, Fukuda T, Suga K, Iwao M, Ishibashi F, Sato H, Kubo Y. Viruses 14 816 (2022)
  296. Using the antibody-antigen binding interface to train image-based deep neural networks for antibody-epitope classification. Ripoll DR, Chaudhury S, Wallqvist A. PLoS Comput Biol 17 e1008864 (2021)
  297. Vaccine-Mediated Induction of an Ebolavirus Cross-Species Antibody Binding to Conserved Epitopes on the Glycoprotein Heptad Repeat 2/Membrane-Proximal External Junction. Cagigi A, Ploquin A, Niezold T, Zhou Y, Tsybovsky Y, Misasi J, Sullivan NJ. J Infect Dis 218 S537-S544 (2018)


Quick links